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Background: Coronary artery bypass grafting (CABG) surgery and percutaneous
coronary intervention (PCI) procedures have been associated with substantial financial costs
in Texas. The annual hospital charges in 2016 for CABG surgeries and PCI procedures in
Texas were $3.6 billion and $4.1 billion, respectively. Recently, these two procedures have
become a target for bundled payment initiatives. Due to the lack of information about the
demographics and variations associated with CABG and PCI episode payments for
commercially insured patients, more research needs to be conducted to understand the
magnitude of payments and the drivers of variation in payments in Texas. Objective: This
study aimed to fill the gap by examining CABG and PCI medical costs through episode
payment models. The first objective was to estimate both CABG and PCI episode payment
variations in patient demographics for a large sample of the commercially insured population
in Texas. The second objective was to examine the payment components that drive
variability in 90-day episode payments across Texas. Methods: The study design was a
retrospective cohort study of commercially insured patients 18 years of age and older

undergoing CABG surgeries and PCI procedures in Texas regions for the years 2014 to 2018.
Using Optum Clinformatics® DataMart (CDM): administrative claims data. For this study,
the average 90-day episode payment for patients undergoing CABG surgeries and PCI
procedures were first calculated and then assessed if there were wide demographic variations
in the payments. The total 90-day payment was derived as the sum of the procedure and
hospitalization payment and the payment associated with post-discharge utilization. All
dollars were adjusted to 2018 values. Multiple linear regression models were used to identify
factors impacting the 90-day total episode payments. After that, the variation in payments
and the primary drivers of payment variations were identified. Hospitals and regions were
divided into quartiles based on the mean episode payment for CABG surgeries and PCI
procedures. Total episode payments were subdivided into five payment components (index
procedure, professional services, post-acute care, readmission, and pharmacy) to investigate
which components drove variability significantly by comparing them across high- and lowcost quartiles. Results: A total of 999 CABG episodes and a total of 2691 PCI episodes were
identified. The mean (SD) 90-day episode payments at patient level for CABG surgeries and
PCI procedures were $81,330 ($47,382) and $53,842 ($44,603), respectively. Certain patient
factors, including age, patient region, comorbidities, type of insurance, length of stay, and
readmission stage had effects on 90-day episode payments. The average 90-day payment at
the hospital level in the highest- and in the lowest-payment quartiles ranged from $106,148
to $61,028, representing a difference of $45,121 (74%) for CABG surgeries. They ranged
from $74,510 to $33,696, representing a difference of $40,814 (121%) for PCI procedures.
The index procedure was the primary driver of 90-day CABG episode payment variation of
49%, while both the index procedure and the post-acute care were relatively similar sources

of 90-day PCI episode payment variation of 37% and 36%, respectively. Conclusions:
Payment variations existed widely in 90-day episode payments for commercially insured
patients undergoing CABG surgeries and PCI procedures across Texas. Focusing on reducing
readmissions and targeting the index payment component, which has contributed to a large
proportion of episode payment variations, might be a potentially effective approach when
developing initiatives to reduce CABG- and PCI-related costs and improve efficiency.
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BACKGROUND
Coronary revascularization procedures (CRPs), such as coronary artery bypass
grafting (CABG) surgery and percutaneous coronary intervention (PCI), are common
invasive procedures for patients with coronary artery disease (CAD). According to the
National Center for Chronic Disease Prevention and Health Promotion, Division for Heart
Disease and Stroke Prevention (DHDSP), CAD is a term for “a plaque buildup in the wall of
the [coronary] arteries that supply blood to the heart [which] causes the inside of the arteries
to narrow over time.”[1] As a result, the growing plaque limits the blood to the heart, which
results in a reduced supply of oxygen to the heart. Consequently, patients with CAD have a
high risk of angina, which is chest pain or discomfort, as well as a myocardial infarction
(MI), which is commonly known as a heart attack.[2] Patients with significant plaque buildup
will often undergo a CABG surgery or a PCI procedure.
CABG is an invasive procedure that uses the patient’s own veins to bypass narrowed
coronary arteries to restore the blood flow to the heart.[3] Not only does the surgery reduce
and relieve chest pain, but it may also prolong life for patients with severe CAD.
Alternatively, PCI is a minimally invasive nonsurgical procedure that opens up the blocked
coronary arteries to improve blood flow in one or more parts of the coronary circulation.[4]
Coronary revascularization with PCI primarily involves the use of balloon angioplasty and
intracoronary stenting.[4] Both CABG surgeries and PCI procedures have been common
clinical interventions for patients with CAD.
There are numerous risk factors that contribute to CAD. These risk factors include
poor diet, physical inactivity, and smoking. In addition, people who have high blood
1

pressure, high cholesterol, diabetes, or a family history of the condition are more likely to
develop CAD.[5, 6] Approximately half of American adults have one of the following risk
factors: smoking, high blood pressure, and/or high cholesterol.[7]The risk for CAD increases
for men starting at age forty-five, while the risk for women increases starting at age fiftyfive.[5, 8] The health prognosis of men with CAD after treatment is better than that of
women’s for short-term revascularization.[9-12] Females have higher mortality, and they are
more likely to suffer major adverse cardiovascular events than males after undergoing CABG
or PCI procedures.[9, 10]
The prevention and intervention levels of care for CAD can be classified as primary,
secondary, and tertiary.[13] The primary level includes taking action to control risk factors
with medications and making healthy lifestyle changes such as exercising, ceasing smoking,
and controlling high blood cholesterol and high blood pressure. The secondary level includes
undergoing non-invasive CAD screening diagnostics (e.g., positive emission tomography,
electrocardiogram, CT, and general imaging) as well as taking medications (e.g., antiplatelet
therapy and beta-blockers). The tertiary level includes undergoing invasive diagnostic
procedures (e.g., angiography) and coronary revascularization procedures (e.g., CABG
surgeries and PCI procedures).
In 2018, the American Heart Association (AHA) reported that the annual medical
costs associated with CAD ($9 billion) make it one of the ten most expensive health
conditions treated in U.S. hospitals.[8] In addition, medical costs related to CAD were
projected to increase by about 100 percent between 2013 and 2030.[8] Medical spending on
CRPs (i.e., CABG surgeries and PCI procedures) in the United States is extremely high
2

compared to other-similar high income-countries, including Canada, the United Kingdom,
and Switzerland. For example, a previous study found that CABG in the United States is
approximately twice as expensive compared to Canada.[14] Furthermore, in 2014, the average
cost (in employer-sponsored plans) for a CABG surgery in the United States was $78,318,
whereas the average cost (average private sectors) was $24,059 in the United Kingdom and
$34,224 in Switzerland.[15, 16] Moreover, the average cost (in employer-sponsored plans) for a
PCI procedure in the United States was $31,620, whereas the average costs (average private
sectors) for a PCI procedure in the United Kingdom and Switzerland were $7,264 and
$10,066, respectively.[16] In light of the reported high costs of CABG and PCI nationwide, it
is necessary to begin investigating these costs statewide as well.
CAD and the Costs of CABG and PCI in Texas
In 2014, the leading cause of death in Texas was CAD, resulting in 175.8 deaths per
100,000 people.[17] In 2016, 1.64 million adults over 18 (6.1% of the population) were
diagnosed with CAD.[17, 18] Not only is CAD Texas’ biggest killer,[19] but it is also one of the
costliest health conditions.[20] The costs of CABG and PCI procedures in Texas have
previously been assessed only to a very limited extent. To our knowledge, costs were not
measured by private insurance payments (i.e., from a payer perspective) but by billing
charges despite the fact that in 2016, more than forty-eight percent of Texas’ population was
covered by private insurance.[21] Moreover, private insurance in Texas has not been effective
at controlling hospital inpatient care payment and, consequently, it was the key driver of
regional variation in healthcare spending in Texas.[22] In fact, Texas had the third highest
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annual average spending growth rate (6.9%) in private health insurance between the years
2001–2014 among all the states.[23]
Differentiating among the terms cost, charge, and reimbursement is a vital step for
understanding healthcare cost studies. The term cost could be considered and evaluated from
different perspectives. To patients, cost is the amount payable out-of-pocket for healthcare
services. [24] To providers, cost becomes the expense incurred to deliver healthcare services
to a patient.[24] To payers, cost includes the amount payable to the provider for rendered
healthcare services to a patient.[24]
Billing charges have been described as the amounts that healthcare providers asked
for the provided services. However, commercial payors generally offer plans that contract
with healthcare providers for rates discounted from charges, causing the charges to be an
inaccurate reflection of actual payments to providers. Reimbursement is the amount that a
third-party payer negotiates as payment to healthcare providers (typically less than the
amount of the billing charge).[24, 25] The reimbursement amount may be in different forms
such as fee-for-service, per diem, capitation, or episode of care (e.g., diagnosis-related group
[DRG]).[25] For the purpose of this research, episode payments referred to reimbursements.
They have been described as the allowed amounts, including insurance company net pay and
insured member out-of-pocket payments (e.g., co-pay, coinsurance, and deductible), to
healthcare providers for the giving medical services.
The Center for Health Statistics in Texas and other state agencies have provided
insight to costs using billing charges as units of cost. For example, hospital charges for CAD
in Texas exceeded $6 billion in 2010 and rose to $8 billion in 2016.[26, 27] According to the
4

Texas Department of State Health Services (DSHS), the average hospital charge for PCI per
case was $126,832 in 2016, while the average hospital charge for CABG surgery per case
was $234,560.[26]
Furthermore, there were considerable variations in the mean charges of CABG and
PCI that had been performed across Texas.[28] For example, in 2016 the approximate mean
charge per case of CABG surgeries performed in El Paso, Houston, McAllen, and Austin in
thousands of dollars were $386, $257, $287, and $236, respectively.[26] The approximate
mean charge per case of PCIs performed in 2016 in El Paso, Houston, McAllen, and Austin
in thousands of dollars were $182, $124, $137, and $141, respectively.[26] These variations in
the charges for CABG and PCI performed in these different areas suggested the need for
further analysis in cost. Patient demographic factors, including patient regions, could have
contributed to the variation in payments. As a result, this study examined medical costs and
variability associated with CABG and PCI treatments throughout Texas.
Hospital Referral Regions
Similar to other states, Texas has a number of hospital referral regions (HRRs)
determined by the Dartmouth Atlas of Health Care (DAHC). These regions reflect
geographic units of analysis to define regional health care markets. They have been defined
by documenting where patients were referred for neurosurgery and for major cardiovascular
surgical procedures.[29] HRRs are comprised of hospital service areas by zip codes grouped
together based on the referral patterns for tertiary and complex medical care.[29] Hospital
service areas were assigned to HRRs where the greatest proportion of major cardiovascular
procedures were performed.[29]
5

Texas has twenty-two different regions, and some of these regions overlap other state
boundaries.[29] In addition, some neighboring state regions overlap Texas boundaries. For
example, there are some New Mexico areas (i.e., Alamogordo, Las Cruces, Deming, Truth or
Consequences) that belong to the Texas El Paso HRR, while there are also some Texas areas
(i.e., Texarkana, Atlanta, Marshall, Carthage) that belong to neighboring state HRRs,
including the Arkansas Texarkana HRR and Louisiana Shreveport HRR. Because each HRR
has at least one city with a hospital where major surgical procedures are performed,
researchers have widely used HRRs as the geographic unit of analysis in their research.[22, 3032]

Episode (Bundled) Payment Models
In an effort to focus on value-based medicine and quality of care in healthcare
spending rather than on volume (i.e., quantity), researchers and policymakers have proposed
clinical episode (bundled) payment models for certain diagnoses and procedures, including
episodes designed around CABG surgeries and PCI procedures.[33-36] The episode payment
typically is a predetermined bundled payment for all the care that a patient receives for a
procedure or treatment of a particular disease or condition during a defined period of time.
An episode may include inpatient stay, professional services, readmission, post-acute care,
and other related services to the inpatient stay and services received within 90-days of the
initial hospital discharge. In episode payment model, healthcare providers participate in this
model through an agreement with payers and receive a set negotiated amount for the multiple
services patients received during an episode of care. Therefore, reimbursement is linked to
the healthcare performance within the episode of care. Healthcare providers are held
6

accountable for the total costs of care and could be subject to financial consequences for lowquality care. Under an episode payment model, healthcare providers through the risk sharing
strategy are incentivized to reduce unnecessary services and improve health care
coordination across healthcare settings.
The Centers for Medicare and Medicaid Services (CMS) is experimenting with
bundled payment approaches, which are also known as episode payment models (EPMs),
with the aim of improving quality of care and reducing costs by aligning incentives among
healthcare providers. In 2013, CMS introduced four voluntary bundled payment
models aiming to increase quality and care coordination at a lower cost.[35, 37] These four
models were included under the Bundled Payment for Care Improvement (BPCI) initiatives.
More bundled models were sequentially introduced, including the first CMS mandatory
model, which was the Comprehensive Care for Joint Replacement (CJR) of 2016.
Furthermore, in 2018, CMS announced a new voluntary episode model for 29 inpatient
clinical episodes and 3 outpatient clinical episodes.[34] This included 90-day time periods for
CABG and PCI episodes to have insight into the events occurring to patients after discharge.
Furthermore, the Quality Payment Program, which was established by the Medicare
Access and CHIP Reauthorization Act of 2015 (MACRA), considered CABG and PCI
episodes as Advanced Alternative Payment Models (Advanced APMs) used to modify
healthcare providers’ payments.[38, 39] One of the goals of these models is to reduce costs by
reducing the amounts of variations in high-cost surgical procedures, including CABG
surgeries and PCI procedures. With the recent heightened focus on payment reform and
increased interest in applying EPMs for Medicare populations, these models are also likely to
7

be embraced by private payers.[36, 40, 41] For example, private employers and the Medicaid
program of Arkansas have already started episode payment initiatives for CABG surgeries
and PCI procedures.[42]
Previous research has shown a wide variation in Medicare post-acute care payments
between hospitals that participated in bundled payments and those that did not.[43-45] Such
studies found that episode payments for surgical procedures, including lower extremity joint
replacement, might have the potential to decrease healthcare payments while maintaining or
improving quality of care.[44-47] Furthermore, other studies found that bundled payments for
joint replacement and for shoulder arthroplasty procedures led to a significant decrease in
costs as well as a significant decrease in readmission rates.[48, 49] Studies that examined
clinical episodes related to cardiac surgeries (i.e., cardiac valve replacement, CABG) found
that bundled payment initiatives were not associated with the index procedure costs but that
they were associated with lowering post-acute care spending.[44, 46]
As CABG and PCI are common but expensive for patients with heart disease,[8] these
procedures might be the first heart disease treatments targeted for mandatory episode
payments. Payers, cardiology specialists, policy makers, and other parties have been making
efforts to ensure that cost-effective care and high-value care are delivered consistently for all
CAD patients.
The present study focused on understanding the drivers of episode payment variation
in CABG surgeries and PCI procedures for privately insured populations in Texas. This study
aimed to provide an understanding of medical care payments in Texas among commercially
insured patients undergoing CABG surgeries and PCI procedures. This study could provide
8

healthcare payers and providers baseline data for the implementation of sound policies for
cost reduction and quality improvement in CAD treatment. To this end, patient factors that
have an impact on episode payment for commercially insured patients having CABG and
PCI in Texas were discussed. This study also assessed the episode payment components
(index procedure payment, professional services payment, post-acute care payment,
readmission payment, pharmacy payment) that drove payment variation.
Literature Review
Variations in healthcare costs could be analyzed by using different methodologies to
estimate costs. Healthcare costs were tracked using different bases, including but not limited
to cost per episode-of-care basis, cost of overall medical care basis, cost within a treatment
level basis, cost within a geographic level basis, and cost within a hospital level basis.[22, 50-54]
Healthcare costs could also be tracked on a spending per beneficiary basis and total per
capita cost basis.[22, 50, 53, 54] Many cost analysis studies also focused on clinical episodes,
including surgical procedures such as hip replacement, knee replacement, back surgery,
colectomy, bariatric surgery, prostatectomy, nephrectomy, carotid endarterectomy, and
lumbar spinal surgery.[55-63] More importantly, several studies have focused on the drivers of
payment variation,[31, 51, 55, 56, 58-64] including PCI cost variations,[52, 64] and CABG cost
variation.[31, 51, 55, 59, 61]
In particular, the PCI procedure cost variation has been explored in at least two
studies. Hsia et al. (2014) found that average cost, which was measured based on hospital
billed charges, varied widely among hospitals for patients undergoing PCI in
California.[52] Also, Sukul et al. (2019) examined PCI episode payment variation and its
9

drivers from 2012 to 2016, considering insurance payment amounts instead of
charges.[64] After comparing the high- and low-payment hospitals in Michigan, Sukul et al.
concluded that a wide variation existed in 90-day episode payments and that readmission
payment was the component with the highest contribution (46.2%) to variation in PCI
episode payments.[64] These two studies were conducted in two different states (California
and Michigan) and indicated that variation in costs for PCI procedures existed statewide.
Similarly, a recent study by Guduguntla et al. (2018) examined CABG episode
payment variation and its components in seventy-six hospitals in Michigan, and these
researchers found that a wide variation existed in 90-day episode payments.[51] The study
found that patients with multiple readmissions as well as components such as index
procedure, evaluation and management services, and inpatient rehabilitation contributed the
most to variation in episode payments.[51] Furthermore, the findings of the study indicated
that among all payment components, readmission had the highest difference rate between the
highest payment hospitals compared with the lowest payment hospitals.
In a recent study in 2019, Shubeck et al. investigated CABG episode payment
variation of Medicare nationwide beneficiaries at the hospital level.[61] These researchers
found that payment variation between the high- and low-payment hospitals was because of a
threefold difference in index procedure payment.[61] The findings of the study demonstrated
that patients with comorbidities incur higher costs than healthier patients. Furthermore, other
research studies on CABG episode payments for Medicare beneficiaries found that
significant payment variation existed for CABG episodes.[55, 59] These studies also found that
the index procedure component was the key driver of payment variations.[55, 59] Because these
10

CABG cost analyses studies focused on Medicare populations, their findings might not be
generalizable for younger populations or for those with private insurance.[55, 59, 61]
A study by Wynn-Jones et al. (2019) examined 90-day period CABG payment
variation targeting the TRICARE adult population and found that significant regional-level
variation in payment for CABG episodes.[31] This study demonstrated that the payment
patterns in the TRICARE data were different from those observed in the Medicare data. The
index procedure payment, which was described as the estimate amount for CABG
hospitalization, was the main driver of payment variations. Moreover, the readmission
payment had the highest difference rate between the highest payment regions compared with
the lowest payment regions. Table 1 summarizes a variety of previous cost variation studies
on CABG and PCI episodes.
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Table 1: Reviewed Studies
Component with the
Author

Clinical

(Year published)

Episodes

Main Measure

Amount

Highest

Study Characteristics

Contribution (%) to
Variation in Costs

Hsia et al. (2014)[52]

PCI

Median hospital charges

$88,350

N/A

Sukul et al. (2019)[64]

PCI

Mean Medicare

$24,696

Readmission

reimbursement
Birkmeyer et al. (2010)[55]

CABG

Mean Medicare

(46.2%)
$36,049

reimbursement
Miller et al. (2011)[59]

CABG

Mean Medicare

(53.8%)
$42,194

reimbursement
Guduguntla et al. (2018)[51]

CABG

Mean Medicare

CABG

Mean Medicare
reimbursement

Wynn-Jones et al. (2019)[31]

CABG

Mean TRICARE payment

Index procedure
(45.6%)

$48 571

reimbursement
Shubeck et al. (2019)[61]

Index procedure

Index procedure
(49%)*

$77,788**
$20,814***

Index procedure

$44,983

Index procedure

(50%)

(57%)

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Variation in index procedure charges at hospital level
Commercially insured patients in California
Study period: 2011
Variation in 90- day episode payment at hospital level
Medicare and BCBS patients in Michigan
Study period: 2012 to 2016
Variation in 30- day episode payment at hospital level
Medicare beneficiaries nationwide
Study period: 2005
Variation in 30- day episode payment at hospital level
Medicare beneficiaries nationwide
Study period: 2005 to 2007
Variation in 90- day episode payment at hospital level
Medicare (>75%) and BCBS patients in Michigan
Study period: 2012 to 2015
Variation in 30- day episode payment at hospital level
Medicare beneficiaries nationwide
Study period: 2010 to 2013

•
•
•

Variation in 90-day episode payment at HRR level
TRICARE beneficiaries nationwide aged 18-65
Study period: 2011 to 2014

*Rate was calculated manually from the article results using the equation of contribution of payment variation (see Equation 2)
**The highest decile mean payments
***The lowest decile mean payments
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Substantial gaps remain in our knowledge of the determinants of the economic burden
of invasive heart procedures in Texas. There is a lack of studies about medical care costs for
commercially insured patients undergoing CABG and PCI procedures in Texas. In addition,
moving from the existing volume payment model (fee-for service) to a model that focuses on
value and bundled payments of healthcare spending poses daunting challenges.
In the case of Texas, it was indicated that unexplained variability in healthcare costs
have been observed. In the article “The Cost Conundrum,” Gawande (2009) explored the
significant Medicare cost variation between McAllen and El Paso, two areas with similar
disease burden and patient demographics.[65] The findings indicated that McAllen had almost
twice the Medicare spending per person in 2006 compared to El Paso. It was unclear why
such variation in costs occurred between two comparable areas within the same state. In
response to this article, research was conducted on the medical costs of the two regions using
a commercially insured population.[30] This follow-up study was found that total spending per
member per year in McAllen was seven percent lower than in El Paso for a privately insured
population.[30] Because this study considered only two regions in Texas, further research on
Texas geographic variation in healthcare costs was recommended.
It was expected that even for well-defined procedures, such as a CABG and PCI
procedures, there would be an observation of unexplained variability in episode payments. In
this present study, episode payments were estimated for both CABG and PCI procedures for
patients in multiple Texas regions. More specifically, this study estimated the payment
components (i.e., index procedure payment, professional services payment, post-acute care
payment, readmission payment, pharmacy payment) as well as mean payments in Texas.
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This study then explained the proportion of the observed variation after accounting for
patient factors. The results of this study may interest policymakers, healthcare payers, and
healthcare providers for designing policies and initiating clinical quality improvements. The
findings of this study could be used for future cost-effectiveness analysis of interventions for
CAD.
Statement of Problem
The cost of treatments for cardiovascular diseases, including CAD, continues to
increase for public and private payers.[8] The literature showed public payers have done a
better job in controlling prices than private payers in Texas.[22] Prices paid to hospitals in
Texas by private payers were 244% higher relative to public payers.[66] Variability in
healthcare spending is hurting efficiency and causing spending waste. It has been found that
both price and utilization drove variation in spending across Texas.[22] Despite the effect and
magnitude of CAD and associated invasive treatments in Texas, there has been limited
examination of cost variation and cost drivers associated with CAD treatments, especially the
costly but common invasive procedures of CABG and PCI. In order to support policymakers,
payers, and hospitals, it is important that rigorous quantitative studies be conducted to
understand CABG and PCI episode payments for commercially insured patients in Texas.
Examining payment components and geographic variation associated with average
payments for commercially insured patients undergoing CABG or PCI across Texas would
help establish policies to improve efficiency and decrease wasteful spending in healthcare in
Texas. The purpose of this research was to describe CABG and PCI episode payment
components and to examine payment variation using a Texas representative commercially
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insured cohort. Medical providers, health insurers, and policymakers who better understand
influencing factors and cost drivers may design initiatives to reduce healthcare spending
through value-based payments and may develop strategies for bundled payments for CABG
surgeries and PCI procedures.
Public Health Significance
An objective assessment of the economic burden of an invasive heart intervention
leads to a better allocation of public health and healthcare resources. Estimating the payment
for an invasive clinical intervention requires a better understanding of the relevant incurred
costs. Such studies inform employers, insurers, and providers what cost elements have
significant impacts on total episode payments.
The prevalence of morbidity and mortality associated with heart disease is noticeable
in Texas.[17, 18] Moreover, the considerable expenditures and volume of CABG surgeries and
PCI procedures reflect the importance of conducting a relevant cost analysis study using
clinical episode models. A cost analysis study of CABG and PCI episode payments for the
Texas population 18 years of age and older is crucial, given that patients aged 45 and 55 for
males and females, respectively, are at-risk for CAD. Furthermore, one study found that 30%
of the patients hospitalized for heart attacks from 1995 to 2014 were between the ages of 35
and 54, and there was a 5-percentage point increase in the number of younger heart attack
victims over that period.[67] In addition, the target population of this study, patients 18 years
of age and older, represented a high proportion of the Texas labor force; therefore, an adverse
financial effect on this population would have significant economic impact on employer
sponsored health plans.
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Study Goals
The goals of this study were the following: 1) to examine variation in CABG and
PCI episode payments across Texas and 2) to examine the payment components that drive
the variability.
Specific Aims
Aim 1A: To evaluate the variation in 90-day CABG episode payments in the Texas
HRRs among commercially insured patients 18 years of age and older undergoing CABG
surgeries by using Optum claims data from 2014-2018, controlling for patient age, gender,
and comorbidities.
•

H0: 90-day CABG episode payments are equal among the Texas HRRs for commercially
insured patients.

•

Ha: At least one HRR in Texas has a significantly different 90-day CABG episode
payment from the other regions for commercially insured patients.
Aim 1B: To evaluate the variation of the 90-day PCI episode payments in Texas

HRRs among commercially insured patients 18 years of age and older undergoing PCI
procedures by using Optum claims data from 2014-2018, controlling for patient age, gender,
and comorbidities.
•

H0: 90-day PCI episode payments are equal among the Texas HRRs for commercially
insured patients.

•

Ha: At least one HRR in Texas has a significantly different 90-day PCI episode payment
from the other regions for commercially insured patients.
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Aim 2A: To examine how the payment components (index procedure, post-acute
care, professional services, readmission, pharmacy) drive variability in the 90-day CABG
episode costs in Texas among commercially insured patients 18 years of age and older for
Optum claims data from 2014-2018.
Aim 2B: To examine how the payment components (index procedure, post-acute
care, professional services, readmission, pharmacy) drive variability in the 90-day PCI
episode costs in Texas among commercially insured patients 18 years of age and older using
Optum claims data from 2014-2018.
Conceptual Framework
For this study, using the Donabedian conceptual framework to measure costs of
CABG and PCI episode payments provided an understanding of the primary outcome
payment for the two defined procedures across different facilities and providers. The
framework was useful for recognizing the different measures in terms of the classical
structure-process-outcome Donabedian triad. For the structure measures, the study included
patient demographics (age, gender, region, comorbidities). For the outcome measures, there
were the two primary outcomes (i.e., 90-day CABG episode payment, 90-day PCI episode
payment) as well as five secondary outcomes (index procedure payment, professional service
payment, post-acute care payment, readmission payment, and pharmacy payment). The
Donabedian framework was an appropriate approach for aggregating claims data into
episodes to assess specific invasive procedure associated payments. As a result, the proposed
conceptual model was developed (see Figure 1) for this study to estimate factors and to
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identify cost drivers contributing to the 90-day episode payments of CABG and PCI
procedures across Texas.
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Figure 1: Conceptual Model for the Measurement of Episode Payments, CABG & PCI
Structure

Process

Outcome
Episode Payment
A. 90-Day CABG Episode Payment ($)

Patient Factors
•

Age

•

Gender

•

Region

•

Comorbidities

Aim 1A

B. 90-Day PCI Episode Payment ($)

Aim 1B
Aim 2A

Aim 2B

Payment Components
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•

Index Procedure Payment ($)

•

Professional Services Payment ($)

•

Post-acute Care Payment ($)

•

Readmission Payment ($)

•

Pharmacy Payment ($)

METHODS
The present research focused on commercially insured patients 18 years of age and
older who were covered by private insurance and who underwent CABG surgery or a PCI
procedure for the years 2014-2018. This study used Optum administrative claims data of a
commercially insured population to identify payments and to quantify episode payment
variation related to these CABG surgeries and PCI procedures across Texas. Payments were
represented by commercial insurance payers in terms of the total cost amounts for the index
procedure and the 90-day care after procedure for patients who underwent CABG surgery or
PCI procedure. The episode payment included payments related to index procedure,
professional services, post-acute care, readmissions, and prescription drugs. For inpatient
clinical episodes, this study computed cost information for medical care from the date of
hospital admission to 90-days post-discharge. For outpatient clinical episodes, it computed
payment information from the index procedure date to 90-days post-discharge. Although this
study was based entirely on commercially insured patients undergoing CABG surgeries and
PCI procedures from 2014-2018, it excluded information for patients discharged toward the
end of 2018 (if the 90-day post-procedure requirement occurred in 2019).
Study Design
This research was a retrospective cohort study using secondary datasets. All patient
records were de-identified. Records of the appropriate Texas population were selected form
the database, which included those patients that underwent coronary revisualization
procedures, CABG surgeries or PCI procedures, from January 1, 2014, to October 2, 2018.
All patients in the present study were included because they were identified to have had
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CABG surgeries or PCI procedures at some point during the study timeframe. Although the
study period was from 2014 to 2018, claims data from 2013 were obtained and used to track
patient comorbidities. Each of the patients was followed through the defined study period to
estimate total episode payments. The episode period referred to index procedure plus a 90day post-procedure follow up period. The 90-day period was used because it is the same
length of time employed by CMS in its EPM design for CABG surgeries and PCI
procedures.[34] The term 90-day episode payment was used in this research, and this term
seemed reflected a payment for a total window of 90-day period for each episode of care.
However, this period in reality is more than 90-days depending on the hospitalization period,
which could have added a few days. Geographic regions in Texas were defined by
aggregating data at the patient zip code level to the HRR level (see Figure 2). All analyses
were performed from a payer perspective.
Sampling Frame and Study Population
The sampling frame of the study included all insured members of Texas HRRs
through a single private payer from 2014 to 2018. For conditions where CABG surgeries and
PCI procedures have occurred, insured patients were in at least 270 days of continuous
enrollment. All patients in this study had been enrolled for at least 180 days prior to the
CABG surgery or PCI procedure and at least 90 days post-discharge. As a result, claims data
from 2013 were obtained to track prior comorbidities for patients who underwent CABG
surgeries or PCI procedures during the first half of 2014. All members were enrolled in feefor-service plans (i.e., preferred provider organizations [PPO] and point of service plans
[POS]). For the study, the procedures of interest (CABG and PCI) were detected according to
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specific inclusion and exclusion criteria. Complete enrollment observations were included
with health plans of fee-for-service payment, including PPO and POS plans. Patients who
underwent CABG surgeries or PCI procedures were identified according to the diagnosis and
procedure codes (see Appendices A & B). All observations in the study were limited to
patients who were 18 years of age and older as of the index procedure admission date.
Insured members within HRRs that belong to other states were excluded. Patients that had
claims with inappropriate or missing data (missing zip codes, inappropriate or missing
admission dates or discharge dates of index procedures) were also excluded. Readmission
payments were included for readmitted patients within 90-days after discharge the date of the
index procedure. Patients who died during the episode window could not be identified;
instead; patients, with zero claims during the 90-days post-discharge were excluded.
Texas is the second largest state, and it has the second largest population in the
United States, which is why it is ideal for obtaining information for a large number of CRPs.
For example, in Texas, the number of reported CABG surgeries and PCI procedures in 2016
were 15,876 and 33,750, respectively.[26] As a result, a significant number of cases were
expected by using Optum claims database, which covers a considerable number of the
commercially insured patients in Texas.[68] For the claims data extraction, this study used the
diagnosis and procedure codes established by the Healthcare Effectiveness Data and
Information Set (HEDIS) and obtained from the Center for Healthcare Data at The
University of Texas Health Science Center at Houston School of Public Health as well as the
trigger codes by the CMS.[69]
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Both Current Procedural Terminology (CPT) codes and Medicare Severity Diagnosis
Related Group (MS-DRG) codes were used to identify PCI procedures because both inpatient
and outpatient settings perform PCI. This was an important aspect of PCI insurance payment.
Among PCI episodes, episodes were included when the CPT codes (i.e., 92920, C9600,
C9604, 92924, 92937, 92928, 92943, C9606, C9606, 92933, C9602, C9602, C9607) and
DRG codes (i.e., DRG 246, DRG 247, DRG 248, DRG 249, DRG 250, DRG 251, DRG 273,
DRG 274) indicated that the PCI procedure was performed during the episode index
procedure.
In contrast, only MS-DRG codes were used to identify CABG surgeries because
CABG is performed only in inpatient settings. Among CABG episodes, episodes were
included when the DRG codes (i.e., DRG 231, DRG 232, DRG 233, DRG 234, DRG 235,
DRG 236) indicated that CABG was performed during the index procedure. Although the
inclusion and exclusion criteria in this study affected the sample size, the total number of all
CABG and PCI episodes identified were (n=3,690).
Variables and Measures
The primary outcome variable for the study was total 90-day episode payment. The
secondary outcome variables were the five payment components: (1) index procedure
payment, (2) professional payment, (3) post-acute care payment, (4) readmission payment,
and (5) pharmacy payment. All these payment variables were continuous variables and
classified by the type of the performed index procedure, CABG surgery or PCI procedure
(see Table 2). Instead of focusing on provider submitted charges, this study focused on the
allowed amounts. The window of the 90-day post-discharge allowed for the evaluation of
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healthcare services that may extend beyond 30-days after the initial CABG surgery or PCI
procedure. All payment variables were measured in 2018 U.S. dollars. The Personal
Consumption Expenditures Health (PCI-Health) Index was used for the analysis of
healthcare expenditure across each year of the study (see Appendix D).[70] The PCI-Health
Index was recommended by the Agency for Healthcare Research and Quality (AHRQ) and
was found to be the appropriate price index to reflect healthcare expenses.[71]
The study also included other variables that represented patient factors, operative
factors, and postoperative factors and whose relationship with total episode payments was
examined. The patient variables of interest were age, gender, region, health plan, insurance
type (i.e., Medicare Advantage, commercial), and comorbidities presented at admission. Age
was a continuous variable measured in years. Gender, health plan, and insurance type were
binary variables. Region was a nominal variable that represented the patient regions of
Texas. Comorbidities were determined based on the Charlson Comorbidity Index (CCI)
scores (see Appendix C). The CCI score was calculated according to the scoring system
established by Charlson which takes into account the associated weight for each comorbid
condition.[72] For example, patients with a CCI score of zero indicated that they have no
records of comorbidities. The variables of comorbid conditions were also measured as binary
variables to understand the impact of each comorbidity on CABG and PCI episode payments.
In addition, the study included operative factors that were related to a patient’s
condition when the index procedure was performed. The CABG episodes of major
complication and comorbidity DRGs (i.e., 231, 233, 235) at the index procedures were split
from those without major complication or comorbidity DRGs (i.e., 232, 234, 236). This DRG
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intensity variable was examined with the 90-day CABG episode payments and also used for
the subgroup analysis. Conversely, the PCI episodes were stratified based on whether the
index PCI was performed for an indication of acute myocardial infarction (AMI) or not. The
diagnosis codes from the literature (see Appendix F) were followed for identifying PCI
episodes with AMI.[64]
Lastly, the study included two postoperative factors, which were length of stay and
readmission stage. Length of stay was a continuous variable, measured in number of days
from admission date to discharge date. Outpatient PCI episodes were given a length of stay
of zero. Next, the readmission variable was a nominal variable, measured by the identifying
period at which the first readmission had occurred. The readmission stage variable had four
categories: non-readmitted patients, readmitted patients within 30 days, readmitted patients
within 31 to 60 days, and readmitted patients within 61 to 90 days. As a result, three dummy
variables were created for the readmission variable to be used in analyses of the regression
models. Table 2 describes all these variables of interest as well as their measurements.
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Table 2: Variable Measurement Matrix for CABG & PCI
Variable

Definition

Link
to Aim

Type of
Variable

Total estimate of allowed amount episode, including index CABG
hospitalization and 90 days after discharge and including all five payment
components (index procedure payment, professional payment, post-acute
care payment, readmission payment, pharmacy payment); all amounts
calculated in 2018 US dollars
90-day PCI episode
Total estimate of allowed amount episode, including index PCI procedure
payment
and 90 days after discharge and including all five payment components
(index hospitalization payment, professional payment, post-acute care
payment, readmission payment, pharmacy payment); all amounts calculated
in 2018 US dollars
Secondary Outcome Variables (Episode Payment Components)

Aim 1
Aim 2

Continuous

Aim 1
Aim 2

Continuous

Index procedure
payment

Aim 2

Continuous

Aim 2

Continuous

Aim 2

Continuous

Aim 2

Continuous

Aim 2

Continuous

Primary Outcome Variables
90-day CABG episode
payment

Professional services
payment
Postacute care payment

Readmission payment

Pharmacy payment

Total estimate of allowed amount for index procedure or index procedure or
hospitalization from admission date to discharge date, calculated based on
the estimate of allowed amount of type of service variable in the dataset
Total estimate of allowed amount for all professional services of the episode,
calculated based on the estimate of allowed amount of type of service
variable in the dataset
Total estimate of allowed amount for all post-acute care type of service of the
episode window, calculated based on the estimate of allowed amount of type
of service variable in the dataset
Total estimate of allowed amount for readmitted patients within 90 days after
index procedure discharge date, calculated based on the estimate of allowed
amount of type of service variable in the dataset
Total estimate of allowed amount for prescription drugs of the episode
window, calculated based on the estimate of allowed amount of pharmacy
claims of the dataset
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Independent Variables
Invasive procedure
A binary variable identifying the episode type whether CABG or PCI;
0=PCI, 1=CABG
Age
Patient age in years derived by calculating the difference between the year of
admission date and the year of birth
Gender
A code identifying the sex of the member at enrollment;
0=male, 1=female
Region
Patient hospital referral region (HRR) of Texas identified according to
patient zip code
Myocardial infarction
Previous patient condition of myocardial infarction for a minimum of a 6month period prior the index procedure admission date; 0=No, 1=Yes
Congestive heart failure Previous patient condition of congestive heart failure for a minimum of a 6month period prior the index procedure admission date; 0=No, 1=Yes
Peripheral vascular
Previous patient condition of peripheral vascular disease for a minimum of a
disease
6-month period prior the index procedure admission date; 0=No, 1=Yes
Cerebrovascular disease Previous patient condition of cerebrovascular disease for a minimum of a 6month period prior the index procedure admission date; 0=No, 1=Yes
Dementia
Previous patient condition of dementia for a minimum of a 6-month period
prior the index procedure admission date; 0=No, 1=Yes
Chronic pulmonary
Previous patient condition of chronic pulmonary disease for a minimum of a
disease
6-month period prior the index procedure admission date; 0=No, 1=Yes
Rheumatologic disease
Previous patient condition of rheumatologic disease for a minimum of a 6month period prior the index procedure admission date; 0=No, 1=Yes
Peptic ulcer disease
Previous patient condition of for a minimum of a 6-month period prior the
index procedure admission date; 0=No, 1=Yes
Mild liver disease
Previous patient condition of mild liver disease for a minimum of a 6-month
period prior the index procedure admission date; 0=No, 1=Yes
Diabetes without
Previous patient condition of diabetes without chronic complications for a
chronic complications
minimum of a 6-month period prior the index procedure admission date;
0=No, 1=Yes
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Aim 1,
Aim 2
Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Continuous

Diabetes with chronic
complications

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Any malignancy,
including lymphoma
and leukemia, except
malignant neoplasm of
skin
Moderate or severe liver Previous patient condition of moderate or severe liver disease for a minimum
disease
of a 6-month period prior the index procedure admission date; 0=No, 1=Yes
Metastatic solid tumor
Previous patient condition of metastatic solid tumor for a minimum of a 6month period prior the index procedure admission date; 0=No, 1=Yes
AIDS/HIV
Previous patient condition of AIDS/HIV for a minimum of a 6-month period
prior the index procedure admission date; 0=No, 1=Yes
Charlson Comorbidity
A weighted score of previous patient conditions for a minimum of a 6-month
Index (CCI) score
period prior admission date, adapted from the Charlson Comorbidity Index
(see Appendix C)
Health plan
This variable identifies the type of fee-for-service plan (i.e., PPO, POS);
0=PPO, 1=POS
Insurance type
This variable identifies the type of business (i.e., commercial, Medicare
Advantage) the product is intended to serve; 0= commercial, 1=Medicare
Advantage
Zip code
Patient’s 5-digit zip code at enrollment

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Continuous

Aim 1

Categorical

Aim 1

Categorical

Aim 1

Categorical

Length of stay (LOS)

Aim 1

Continuous

Hemiplegia or
paraplegia
Renal disease

Previous patient condition of diabetes with chronic complications for a
minimum of a 6-month period prior the index procedure admission date;
0=No, 1=Yes
Previous patient condition of hemiplegia or paraplegia for a minimum of a 6month period prior the index procedure admission date; 0=No, 1=Yes
Previous patient condition of Renal disease for a minimum of a 6-month
period prior the index procedure admission date; 0=No, 1=Yes
Previous patient condition of any malignancy, including lymphoma and
leukemia, except malignant neoplasm of skin for a minimum of a 6-month
period prior the index procedure admission date; 0=No, 1=Yes

Identifies the length of stay in days for index procedure; LOS = Date of
Discharge – Date of Admission, 0=Outpatient PCI episodes
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Readmission range

CABG DRG intensity

AMI PCI

Identifies the 1st all-cause readmission of patients within the 90-days period
post-discharge, was coded as follows:
• 0=no readmission
• 1=within 30-day period post-discharge
• 2=within 31- 60-day period post-discharge
• 3=within 61- 90-day period post-discharge
For the regression model analyses, three dummy variables were created (i.e.,
readmission1, 0=No, 1=Yes; readmission2, 0=No, 1=Yes; readmission3,
0=No, 1=Yes)
Identifies the CABG episodes where the severity of the diagnosis
reported during the index CABG hospitalization included major complication
or comorbidity (MCC) (i.e., MS-DRGs with MCC: 231, 233, 235; MS-DRGs
without MCC =232,234,236); 0=No, 1=Yes
Identifies the PCI episodes where patients admitted for AMI and treated with
PCI; 0=No, 1=Yes

Aim 1

Categorical

Aim 1,
Aim 2

Categorical

Aim 1,
Aim 2

Categorical

Note: The primary source of data for the study variables was Optum claims data
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; PPO, proffered provider organization; POS, point of service plan; MS-DRG, Medicare
severity diagnosis-related group; MCC, major complication or comorbidity; AMI, acute myocardial infarction.
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Data Sources
This research used three different data sources. First, the key data source for this
study was the Optum Clinformatics® DataMart (CDM): administrative claims data. Claims
data have been essential source of information for studies of medical procedure cost analysis
and financial burden of illness. Using claims data is a common approach for tracking and
detecting medical costs of health care procedures for a large population of patients. The
claims data used for this research creates standardized costs and does not reflect the actual
payment. As a result, the claims data standardizes payment in the data set so as not to be
impacted by contract discounting. These standardized costs allowed for making proper
comparisons of payments across Texas by removing variation in negotiated prices between
the insurer and healthcare providers. The claims dataset used for this research included
patient demographic factors (i.e., age, gender, region) as well as clinical characteristics such
as ICD-9/ICD-10 diagnoses that could be used to detect comorbid conditions across
individuals over time. In addition, the claims data included date of services, type of services,
patient zip codes, and dollar amounts associated with rendered procedures (see Appendix E).
The claims datasets for this study were obtained through the University of Texas School of
Public Health (UTSPH), which had signed an agreement for the creation of the research.
Second, publicly available data from the Dartmouth Atlas of Health Care was used
for Texas hospital referral regions (available at
http://www.dartmouthatlas.org/tools/downloads.aspx?tab=39). The Dartmouth zip code to
HSA to HRR crosswalk, allowed the aggregation of data at the zip code level to the HRR
level in Texas and the grouping of patients into relevant geographic regions in the state.[29]
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Third, the United States Census Bureau geospatial data (i.e., shapefiles) were also
used in a geographic information system (GIS) software for this research.[73] The
cartographic boundary shapefile for states was used to describe the patterns of CABG and
PCI costs across Texas. These data were matched to the HRRs form the crosswalk data
obtained by the Dartmouth Atlas of Health Care. Non-spatial tables of CABG and PCI
episode payments to were joined with the spatial table based on HRRs ID field. The United
States Census Bureau data were publicly available (which can be downloaded from
https://www.census.gov/geo/maps-data/data/tiger.html ). They are spatial extracts from the
Census Bureau's MAF/TIGER database, containing the U.S. geographic areas, which were
used to create the desired maps and to display the spatial patters of payments for this study
using ESRI ArcGIS software version 10.6.
Data Analysis
The descriptive statistics for the study episodes were calculated from the two primary
payment variables, which were 90-day CABG episode payment and 90-day PCI episode
payment, and then were compared. The distribution of continuous variables was presented by
calculating their means and standard deviations as well as their medians and interquartile
range values. The distribution of categorical variables was presented as raw counts and
percentages. Statistical inference was conducted using t-tests with alpha = 0.05.
For Aim 1, the study provided descriptive statistics that included the characteristics of
the CABG or PCI episodes of the study population. Frequencies and percentages were
calculated for region, gender, comorbidities, health plan, insurance type, and readmission
stage variables. Means, medians, standard deviations, and interquartile ranges were
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calculated for age, length of stay, and CCI score variables. The tests of comparisons between
CABG and PCI episodes of the study population were Fisher’s exact tests for binomial
variables, Chi-square (x2) tests for nominal variables, and independent samples t-test for ratio
variables.
In addition, an exploratory spatial data analysis (EDSA) approach was used to reveal
and visualize variations of CABG and PCI episode payments across patient HRRs in Texas.
All zip codes of Texas HRRs were identified using Dartmouth crosswalk data. Then, patient
zip codes (i.e., patient’s 5-digit zip code at enrollment) were associated with the Texas’
HRRs zip codes and HRR map layers to reflect the geographic units of analysis and to define
Texas regional healthcare markets (see Figure 2). This study used HRRs as the geographic
unit of analyses because each HRR represented a healthcare market and had at least one city
with a hospital where major surgical procedures such as CABG surgeries and PCI procedures
are performed.[29] Patient zip codes were used for the current study to identify geographic
unit of analysis instead of hospital zip codes because the claims data did not provide
healthcare provider zip codes. The current study focused on patient level factors and patient
zip codes were considered at patient levels. Furthermore, according to the DAHC, when
patients in the U.S. are admitted to healthcare settings, the admission commonly takes a place
within a close area where patients live and that provide proper level of care.[29]
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Figure 2: Map of Texas Hospital Referral Regions (HRR)
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The 90-day episode payment was the unit of cost. Episode payments were calculated
in 2018 U.S. dollars for commercially insured patients who underwent CABG or PCI
procedures in Texas HRRs. The episode period started from admission date and ended on the
90th day post-discharge within the study timeline of 2014 to 2018. Winsorization was applied
to each of the CABG and PCI episode payments at the 1st and 99th percentiles to minimize
the influence of outliers. As a result, episode payments above the 99th percentile were
adjusted to the payment value of the 99th percentile, and episode payments below the 1st
percentile were adjusted to the payment value of the 1st percentile.
Summary statistics were provided for CABG or PCI episodes across Texas HRRs.
Means, quartiles, and standard deviations were calculated for the outcome variables. Two
tables were provided to demonstrate the variability in total 90-day episode payments among
patient HRRs in Texas for both CABG and PCI episodes. ANOVA tests were used to
compare the mean values of the variables. Furthermore, Kruskal-Wallis tests were run to
compare the median values of the variables. All these statistics tests were performed as
comparative statistics to compare episode payments in terms of the patient characteristics, for
example, comparing the mean episode payments between males and females. Pearson
correlation coefficients were also calculated to explore the relationship between the
continuous independent variables with the outcome variables. These tests provided an
understanding about the strength as well as the directions of these relationships. In addition,
comparisons were performed to measure degree of associations through chi-square and phi
coefficient tests (p <0.05).
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This study used the comorbidity variables as a measure of the burden of disease on
the study population.[72, 74, 75] Patient comorbidities were identified according to diagnosis
codes. To ensure the stability of the analyses in the regression models, the comorbidities that
appeared in fewer than 20 episodes were not considered. For example, the peptic ulcer
disease variable was not included in the regression model of predictors of episode payments
for CABG procedures because there were only 5 episodes with this comorbid condition. A
similar approach has been previously performed in the literature for comorbidities in
regression analysis.[76] Furthermore, this study considered the six main regions of Texas for
the analyses of the regression models and all of the remaining ones were collapsed into one
region.
The Least Absolute Shrinkage and Selection Operator (LASSO) method was used to
select and simplify the number of covariates to include in the regression model. [76] Moreover,
LASSO was performed to select significant predictors of episode payments following a
similar approach that was used in previous clinical outcomes studies.[77, 78] Variables included
in the LASSO method analyses were gender, age, comorbidities that have appeared in fewer
than 20 episodes, length of stay, insurance type, regions, and readmission stage. A DRG
intensity variable was also included for the CABG LASSO analysis. A recent study (2019)
showed that patients who had complications during their index CABG procedure would
significantly impact costs.[79] Also, an AMI PCI variable was included for the PCI LASSO
analysis. The LASSO variables were used on all predictors for log transformed payments of
CABG and PCI episodes. The log transformation was performed to normalize the payment
data as they were found to be positively skewed. In addition, a previous study that compared
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the performance of different regression models for analyzing cost of CABG surgery
suggested that using log transformed cost data demonstrate good consistency in identifying
factors that are significantly associated with increased cost.[80] After completing the LASSO
analysis, the regression models with the LASSO set of variables were performed.
The linear regression models were run to examine the impact of patient characteristics
on the 90-day episode payments for each of the two selected procedures, CABG and PCI.
The regression analyses provided insight into the impact of patient characteristics and other
covariates on 90-day CABG and PCI episode payments in Texas using the following episode
payment measurement equation:
Log(Y) = ẞ0 + ẞ1X1 + … +ẞkXk +Ꜫ.

(1)

The regression models were fitted to predict the log-normalized payment and
investigated to determine the influence of patient factors, where Y is the logarithmic episode
payment variable, ẞ0 is the intercept term, ẞ is the constant regression coefficient, X is the
explanatory variable , k is the number of explanatory variables, and Ꜫ is the residual error. In
addition, collinearity was diagnosed by calculating the variance inflation factor (VIF <10),
and tolerance (T > 0.1).[81] Finally, the exponentiated coefficients were calculated from the
regression models to see if and how patient characteristics significantly predicted episode
payments. The predominant predictors of payments were further inspected. Finally, the most
common causes of readmissions were identified, as well as the readmission rates by patient
regions.
For Aim 2, this study provided descriptive statistics: including summary tables for the
episode payment and the drivers of payment variation across Texas. The episode payment
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was disaggregated into five payment components, which were index procedure, professional
services, post-acute care, readmission, and pharmacy. This study measured and described 90day mean episode payments, mean component payments, and mean subcomponent payments
for both CABG surgeries and PCI procedures.
As the 90-day episode payment was categorized into five components, these
components were classified using two criteria, which were type of service and date of
service. This information was available in the claims data that were used for this research.
Index procedure payment included the total allowed amounts for inpatient facility care and
surgery facility services for the period from the index procedure admission date to the
discharge date, and although proceeded the 90 days post procedure were included in the
episode period. Professional service payments included the total allowed amounts for any
professional services during the episode period. Post-acute care payments included the
allowed amounts for any ancillary and facility services during the episode period, not limited
to care related to CAD. The readmission payment component included the total allowed
amounts for any readmissions during the 90-day post-discharge period. For readmission stays
longer than the 90 days, payments were cutoff at 90 days. This approach of calculating
readmission payments was used in two similar previous studies.[51, 64] Finally, pharmacy
payments included total reimbursements for pharmacy claims during the episode of care.
Inpatient pharmacy costs were included in the inpatient payments.
Furthermore, the study identified subcomponents for professional services as well as
for post-acute care. The professional services were categorized into nine subcomponents,
including evaluation and management (E&M), anesthesia, laboratory, emergency room,
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diagnostic testing, physical medicine/rehab, radiology, surgery, and professional other. Postacute care services were also categorized into nine subcomponents, including home
health/hospice visits, ancillary, rehab/skilled nursing facility, outpatient facility surgery,
outpatient facility laboratory, outpatient facility diagnostic, emergency room, and outpatient
facility other. This study examined the episode payment, which is broken down and
summarized in Figure 3.
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Figure 3: Episode Breakdown

Total Episode Payment

Index Procedure*
o
o

Inpatient Facility
Outpatient
Facility Surgery

Professional
Services

Post-acute
Care

1. E&M
o Office Visits
o Consultations
o Inpatient Visits
2. Anesthesia
3. Laboratory
4. Emergency Room
5. Diagnostic Testing
6. Physical Medicine/Rehab
7. Radiology
8. Surgery
9. Professional Other
o Allergy Tests and Injections
o Immunizations and Injections
o Mental Health
o Pathology
o Preventive Medicine
o Obstetrics
o Vision, Hearing and Speech

Ancillary

o

Facility
3.
4.
5.
6.
7.
8.
9.

Pharmacy

Post-discharge Inpatient Facility

1. Home Health/Hospice Visits
2. Ancillary
o Services and Supplies
o Durable Medical Equipment
o Administered Drugs
o Transportation Services

*Total allowed amount for facility inpatient and facility surgery services for the period from index admission date to discharge date
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Readmission

Rehab/Skilled Nursing Facility
Outpatient Facility Surgery
Outpatient Facility Radiology
Outpatient Facility Laboratory
Outpatient Facility Diagnostic
Emergency Room
Outpatient Facility Other

The differences in mean episode payments among low-payment versus high-payment
hospitals were examined. As a result, hospitals were classified into four quartiles according
to the 90-day mean episode payments for each CABG and PCI episodes. After that, the mean
payments of each component (i.e., index payment, professional services payment, post-acute
care payment, pharmacy payment, readmission payment) between the high- and low-payment
quartiles were compared to determine which component contributed to the greatest
proportion of variation. The rates of payment variations between high- and low-payment
hospitals for both CABG and PCI episodes were calculated as well as demonstrated and
displayed in bar charts. The absolute differences of payments between high-payment and
low-payment quartiles were calculated for each of the payment components and for the
subcomponents. Then, key drivers of payment variation were determined by calculating the
degree to which variation in component payments attributable to the total variation in 90-day
episode payments between high- and low-payment quartiles. The rate of total payment
variation contributed by each payment component was calculated using the following
equation:

Contribution
(%) of
Payment
Variation

=

Average Component
Payment of Highpayment Quartile
Average Episode
Payment of Highpayment Quartile

Average Component
Payment of Lowpayment Quartile
-

X 100.

(2)

Average Episode
Payment of Lowpayment Quartile

The study then described the payment components of the five hospitals with the
highest episode payments by examining payments in each component at the individual
facility level to their payment variation. These five hospitals were ordered from the highest to
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the lowest mean total episode payment and compared with the quartile hospitals and highest
quartile hospitals. These comparisons were performed to observe the payment patterns for
the highest payment hospitals for CABG surgeries and PCI procedures.
After this, two subgroup analyses were performed for the CABG episodes and two
subgroup analyses were performed for the PCI episodes. These analyses examined the
robustness of the calculation method and the results of the model. First, for CABG episodes,
a DRG intensity subgroup (i.e., episodes without major complication and comorbidity for the
index hospitalization) was created to determine if DRG intensity affected the results.
Furthermore, a commercial-only patient subgroup was created because they represented a
high proportion of the study population (83%) and to ensure the results did not vary by
insurance type. A similar approach has been performed in a previous study on CABG
episode payments selecting a subgroup analysis of Medicare-only beneficiaries as they had a
higher proportion of the study population (>75%) than the privately insureds.[51] Moreover,
the same approach was followed for performing the subgroup analyses of PCI episodes. First,
an AMI PCI subgroup (i.e., patients admitted for AMI and treated with PCI) was created to
determine if AMI episodes affected the results. Second, a commercial-only patient subgroup
was created as these patients represented a high proportion (84%) of the present study
population. After that, hospitals were ranked within each subgroup by their mean 90-day
episode payment and categorized into high-payment and low-payment quartiles to calculate
the payment component variation. These subgroup analyses would enhance the
understanding of the sources and magnitudes of payment variations. They would also help to

41

ensure that the calculations had reasonable validity and provided insights into how episode
payment varied across Texas.
Finally, this study examined differences in mean episode payments among lowpayment versus high-payment regions (assuming that patients performed their index
procedure within their regions). Having the HRR as the geographic unit of analysis, HRRs
were categorized into four quartiles based on each region’s 90-day mean episode payments.
Two visual display maps were provided of the mean episode payments across the Texas
HRRs using ArcGIS software. Episode payments were evaluated to compare high-payment
versus low-payment regions, including the mean of each payment component (i.e., procedure
payment, professional services payment, post-acute care payment, readmission payment,
pharmacy payment) between the high- and low-payment quartiles. The absolute differences
between high-payment and low-payment regions were calculated for the payment
components. Then, the rate of total payment variation contributed was calculated for each
payment component. This was done to determine which component contributed (%) the
greatest proportion of variation. Statistical analyses were performed using SAS software
version 9.4, Microsoft Excel version 16.23, and ArcGIS version 10.6.
Ethical Considerations
All claims data for this study were de-identified, and there was no harm to human
subjects, qualifying this study for the Institutional Review Board (IRB) exemption. After
seeking IRB exemption (IRB Number: HSC-SPH-19-0270), all the necessary requirements
of the UTHealth Center for Healthcare Data were completed and submitted to gain access to
the dataset. All data were stored on secure servers within the UTHealth SPH. Access was
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obtained to the extracted datasets of interest through a UTHealth virtual private network,
further ensuring data security. After confirming the proper study design and data
management, this study was carried out.
RESULTS
The starting number of patients who underwent CABG surgeries and PCI procedures
were 4,623 and 14,182, respectively. After applying the inclusion and exclusion criteria, a
total of 999 CABG episodes were identified for 996 patients and a total of 2,691 PCI
episodes were identified for 2,506 patients across the state of Texas from 2014 to 2018 (see
Figure 4). The number of PCI episodes was 69.4% higher than the number of CABG
episodes. Of the 996 identified patients who underwent CABG surgeries, there were 993
patients with one episode and 3 patients with two episodes. On the other hand, of the 2,594
identified patients who underwent PCI episodes, there were 2,506 patients with one episode,
81 patients with two episodes, 6 patients with three episodes, and 1 patient with five
episodes. All patients with multiple episodes were included in the study. As a result, a total
of 3690 episodes were identified: a total of 999 CABG episodes and a total of 2691 PCI
episodes.
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Figure 4: Exclusion Criteria for PCI and CABG Episodes

The UT Center for Healthcare Data
Starting Sample

PCI

CABG

Exclusions

n= 4,623

n= 14,182
n= 4,313

Non-continuous
enrollment

n= 832

Not-within the study
timeframe
(1/1/2014 to 10/2/2018)

n= 9,869

n= 1,513
n= 3,110
n= 361
n= 2,749

n= 9,037
n= 6,379

Non-PPO or -POS plans

n= 1,738
n= 1,011

n= 2,658
n= 12

Not-within the study
regions

n= 11
n= 1,000

n=2,646
n= 14

< 18 years

n= 38

Missing data: patients
with claims having
inappropriate data

n=2,632

n= 0
n= 1,000
n= 4

n = 996
CABG Episodes= 999

n = 2,594
PCI Episodes = 2,691
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Descriptive Statistics
As shown in Table 3, the average age of the CABG episode patients was 61 years,
and the average age of the PCI episode patients was 58.6 years for a difference of 2.4 years
(p <0.0001). The variable age was normally distributed for both CABG and PCI episodes.
There was a significant difference in the distribution of gender (i.e., male, female) in the
CABG and PCI episodes (p =0.0038). However, the proportions of male episodes were
higher than female episodes in both CABG (80.09%) and PCI (76.4%) episodes. Seventeen
comorbid conditions were identified for the study population. The statistically significant
differences in the proportions of comorbidities between CABG and PCI episodes were found
in myocardial infarction (22.62% vs. 15.87%, p <0.0001); congestive heart failure (15.22%
vs. 12.34% , p = 0.0214); peripheral vascular disease (13.01% vs. 6.09%, p <0.0001);
cerebrovascular disease (19.62% vs. 8.40%); diabetes without chronic complications
(25.43% vs. 19.10%, p <0.0001); and diabetes with chronic complications (15.82% vs.
9.07%, p<0.0001). Likewise, there was significant difference between the means of the
Charlson comorbidity score of the CABG episodes and the PCI episodes (1.89 vs. 1.38, p
<0.0001). These distributions were not different for the remaining characteristics of
insurance type (i.e., Medicare Advantage, commercial) or health plan (i.e., PPO, POS).
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Table 3: Characteristics of the Study Population, CABG & PCI Episodes
CABG episodes

PCI episodes

(n = 999)

(n=2691)

61.0 (8.6)

58.6 (10.9)

61 (12)

59 (13)

Male

808 (80.9%)

2056 (76.4%)

Female

191 (19.1%)

635 (23.6%)

Myocardial infarction

226 (22.62%)

427 (15.87%)

<0.0001**

Congestive heart failure

152 (15.22%)

332 (12.34%)

0.0214**

Peripheral vascular disease

130 (13.01%)

164 (6.09%)

<0.0001**

Cerebrovascular disease

196 (19.62%)

226 (8.40%)

<0.0001**

5 (0.50%)

24 (0.89%)

0.2316

154 (15.42%)

360 (13.38%)

0.1122

Rheumatologic disease

23 (2.30%)

68 (2.53%)

0.6958

Peptic ulcer disease

5 (0.50%)

22 (0.82%)

0.3153

Mild liver disease

44 (4.40%)

113 (4.20%)

0.7837

254 (25.43%)

514 (19.10%)

<0.0001**

158 (15.82%)

244 (9.07%)

<0.0001**

4 (0.40%)

15 (0.56%)

0.7960

101 (10.11%)

231 (8.58%)

0.1500

54 (5.41%)

139 (5.17%)

0.7710

Moderate or severe liver disease

2 (0.20%)

9 (0.33%)

0.7377

Metastatic solid tumor

9 (0.90%)

28 (1.04%)

0.1430

AIDS/HIV

1 (0.10%)

3 (0.11%)

0.9256

1.89 (2.03)

1.38 (2.00)

<0.0001**

1(2)

1 (2)

Characteristic
Age

Mean (SD)
Median (IQR)

Gender

P-Value

<0.0001**

n (%)

Comorbidities*

0.0038**

n (%)

Dementia
Chronic pulmonary disease

Diabetes without chronic
complications
Diabetes with chronic complications
Hemiplegia or paraplegia
Renal disease
Any malignancy, including
lymphoma and leukemia, except
malignant neoplasm of skin

CCI score

Mean (SD)
Median (IQR)

Insurance type

n (%)

0.517

Medicare Advantage

170 (17.02%)

434 (16.13%)

Commercial insurance

829 (82.98%)

2257 (83.87%)

Health plan

n (%)

0.585

PPO

175 (17.52%)

451 (16.76%)

POS

824 (82.48%)

2240 (83.24%)

*Comorbidities present in <20 episodes were not considered for the regression analyses.
**Statistically significant at  = 0.05 level.
CCI, Charlson comorbidity index; PPO, preferred provider organization; POS, point of service plan
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Regions of the study population were presented in Table 4. The results showed that
there was a significant difference in the distribution of CABG and PCI episodes by patient
regions (p <.0001). Six regions of the study population accounted for the vast majority of
episodes (i.e., 81% for CABG and 79% for PCI episodes). These six regions were Houston,
Dallas, Austin, Fort Worth, San Antonio, and Corpus Christi.
Table 4: Region of the Study Population, CABG and PCI Episodes
CABG episodes

PCI episodes

Region

(n = 999)

(n=2691)

Abilene

8 (0.80%)

57 (2.12%)

Amarillo

12 (1.20%)

55 (2.04%)

Austin

119 (11.91%)

287 (10.67%)

Beaumont

19 (1.90%)

39 (1.45%)

Bryan

5 (0.50%)

23 (0.85%)

Corpus Christi

45 (4.50%)

68 (2.53%)

Dallas

207 (20.72%)

518 (19.25%)

El Paso

2 (0.20%)

26 (0.97%)

Fort Worth

100 (10.01%)

301 (11.19%)

Harlingen

10 (1.00%)

10 (0.37%)

Houston

262 (26.23%)

670 (24.90%)

Longview

14 (1.40%)

38 (1.41%)

Lubbock

11 (1.10%)

67 (2.49%)

McAllen

17 (1.70%)

26 (0.97%)

Odessa

19 (1.90%)

38 (1.41%)

San Angelo

10 (1.00%)

20 (0.74%)

San Antonio

72 (7.21%)

273 (10.14%)

Temple

17 (1.70%)

51 (1.90%)

Tyler

29 (2.90%)

56 (2.08%)

Victoria

7 (0.70%)

13 (0.48%)

Waco

8 (0.80%)

45 (1.67%)

Wichita Falls

6 (0.60%)

10 (0.37%)

Note: Regions were identified according to patients 5-digit zip codes at enrollment
*Test of comparison was Chi-square (X2) test.
**Statistically significant at  = 0.05 level
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P-Value*

<0.0001**

The descriptive statistics of postoperative factors were presented in Table 5. There
was significant difference between the means of length of stay of CABG episodes and PCI
episodes (8.36 vs. 3.28, p <0.0001). Lastly, there was statistically significant difference in the
proportion of readmission for CABG episodes and PCI episodes by the readmission stage (p
<0.0001).
Table 5: Postoperative Factors of the Study Population, CABG and PCI Episodes
Characteristic
Length of stay

Mean (SD)
Median (IQR)

Readmission stage

CABG episodes

PCI episodes

(n = 999)

(n=2691)

8.36 (4.43)

3.28 (4.34)

7 (4)

2 (1)

n (%)

P-Value

<0.0001**

<0.0001**

No readmission

860 (86.06%)

2283 (84.84%)

within 30-D

68 (6.81%)

190 (7.06%)

within 31- 60-D period

36 (3.6%)

116 (4.31%)

within 61- 90-D period

35 (3.5%)

102 (3.79%)

**Statistically significant at  = 0.05 level.

Total 90-Day Episode Payments for CABG and PCI Procedures
The statewide mean 90-day CABG episode payment over the study period was
$81,330 (SD = $47,382), while the mean 90-day PCI episode payment was $53,842 (SD =
44,603) (see Table 6). The median 90-day CABG episode payment over the study period was
$69,056 (IQR = $42,162), while the median 90-day PCI episode payment was $39,376 (IQR
= $35,873). The distributions of 90-day episode payments were highly positively skewed for
both CABG surgeries and PCI procedures. The 25th percentiles of 90-day episode payments
for CABG surgeries and for PCI procedures were $52,284 and $27,015, respectively. The
75th percentiles of 90-day episode payments for CABG surgeries and for PCI procedures
were $94,446 and $62,888, respectively.
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Table 6: 90-Day Episode Payment Descriptive Statistics for CABG and PCI Procedures
Measure
Mean
SE

CABG episodes

PCI episodes

$81,330

$53,842

1499

860

Median

$69,056

$39,376

SD

$47,382

$ 44,604

Kurtosis

4.65

6.55

Skewness

1.93

2.37

IQR

$42162

$ 35,873

25th percentile

$52,284

$27,015

75th percentile

$94,446

$62,888

Note: Winsorization was applied to episode payments at the 1st and 99th percentiles
SE, standard error; SD, standard deviation

Episode Payments by Patient Characteristics
The mean 90-day CABG episode payments varied by patient factors, including health
plan, insurance type, readmission stage, and certain comorbidities (see Table 7). There was a
statistically significant difference between the mean 90-day CABG episode payment for
Medicare Advantage and commercial patients (p <0.0001). Furthermore, the mean 90-day
CABG episode payments were not all the same among the readmission stages (p <0.0001).
For comorbidities, there was a statistically significant difference between the mean 90-day
CABG episode payment for patients with prior cerebrovascular disease and patients without
(p =0.003), for patients with prior diabetes with chronic complications and patients without
(p =0.004), for patients with prior hemiplegia or paraplegia and patients without (p =0.015),
and for patients with prior renal disease and patients without (p =0.05).
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Table 7: CABG Episode Payments in 2018 Dollars by Patient Factors, Texas 2014–2018
Variable
All
Gender

Male
Female
Health Plan
POS
PPO
Insurance type
Commercial
Medicare Advantage
Readmission stage
No Readmission
Within 30-day period
Within 31- 60-day period
Within 61-90-day period
Comorbidity
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Rheumatologic disease
Peptic ulcer disease
Mild liver disease
Diabetes without chronic complications
Diabetes with chronic complications
Hemiplegia or paraplegia
Renal disease
Any malignancy, including lymphoma
and leukemia, except malignant
neoplasm of skin
Moderate or severe liver disease
Metastatic solid tumor
AIDS/HIV
* p-value was calculated for log payment
**Statistically significant at =0.05 level

Mean (SD)
$81,330 ($47,382)
$79,848 ($45,177)
$87,596 ($55,455)
$84,625 ($49,136)
$65,810 ($34,112)
$84,626 ($49,208)
$65,253 ($32,878)
$74,294 ($40,451)
$123,508 ($59,603)
$122,175 ($64,937)
$130,237 ($64,642)
$83,784 ($47,690)
$90,082 ($57,121)
$88,512 ($56,651)
$74,473 ($45,525)
$52,228 ($17,104)
$82,054 ($48,540)
$85,731 ($62,639)
$70,007 ($24,960)
$89,897 ($42,639)
$77,953 ($41,536)
$95,886 ($61,076)
$153,750 ($84,466)
$101,934 ($70,810)
$75,943 ($40,752)

$42,416
$94,811
$89,108

($25,716)
($45,650)

Median (IQR)
$69,056 ($42162)
$67,893 ($39,933)
$72,478
$71,822
$56,977
$71,813
$56,960
$65,005
$102,738
$118,005
$110,714
$70,394
$73,408
$72,493
$63,931
$60,212
$67,515
$66,664
$69,293
$83,968
$69,545
$76,734
$126,431
$75,401
$66,404

($58,709)
($42,948)
($31,396)
($42,934)
($31,248)
($37,980)
($93,315)
($61,845)
($86,995)
($50,178)
($60,809)
($46,538)
($40,799)
($7,946)
($48,886)
($47,225)
($35,449)
($57,394)
($43,323)
($57,467)
($106,772)
($111,934)
($37,030)

$42,416
$87,221
$89,108

($36,368)
($47,453)

P Value*
0.57
<.0001**
<.0001**
<.0001**

0.35
0.11
0.26
0.003**
0.15
0.99
0.94
0.81
0.13
0.30
0.004**
0.015**
0.05**
0.46

The mean 90-day CABG episode payments were calculated across patient regions
(see Table 8). The p-value of the ANOVA test that was performed to test log transformed
payments among patient regions was significant (p <0.05). Thus, the patient regions of Texas
were not all the same for the mean 90-day CABG episode payments. The p-value of the
Kruskal-Wallis test for CABG episode payments was significant (p = 0.0010), so there was
sufficient evidence that the median 90-day CABG episode payment for insured patients of at
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0.12
0.27
0.68

least one of the regions was different than those for insured patients of the other regions.
Therefore, the median payments for patients of the 22 regions were not equal.
Table 8: Variability in the 90-day CABG Episode Payments Among Patient Regions in
Texas. Regions Ordered from the Lowest to the Highest Mean Episode Payment, Texas
2014–2018
Region

Mean (SD)

All

$81,330

($47,382)

Beaumont

$95,325

($59,084)

Fort Worth

$91,387

Harlingen

P Value*

Median (IQR)
$69,056

($42162)

$83,384

($55,338)

($53,244)

$73,660

($49,326)

$89,115

($78,655)

$61,238

($50,450)

Houston

$88,201

($53,831)

$73,271

($45,746)

Longview

$88,192

($43,755)

$67,320

($40,943)

Lubbock

$87,573

($57,159)

$75,401

($41,985)

Bryan

$85,709

($30,103)

$69,349

($50,149)

Dallas

$84,852

($47,920)

$71,225

($51,230)

Abilene

$83,445

($52,316)

$69,833

($73,887)

El Paso

$82,111

($34,752)

$82,111

($49,147)

Waco

$81,154

($39,438)

$70,240

($57,513)

Tyler

$78,210

($43,518)

$61,377

($37,111)

San Angelo

$75,629

($50,892)

$55,817

($48,129)

Corpus Christi

$75,600

($41,431)

$65,201

($33,069)

San Antonio

$74,187

($28,312)

$68,244

($36,322)

Odessa

$73,386

($30,587)

$70,392

($42,756)

McAllen

$73,271

($34,025)

$58,172

($32,026)

Temple

$72,378

($28,482)

$66,487

($23,110)

Austin

$63,021

($35,242)

$58,984

($35,114)

Amarillo

$60,376

($44,494)

$49,217

($20,879)

Victoria

$59,946

($10,724)

$61,722

($20,823)

Wichita Falls

$57,474

($18,319)

$56,259

($36,659)

<.0001***

P Value**

0.001***

Note: Regions ordered from the lowest to the highest mean episode payment; regions were identified according to patients 5-digit zip codes
at enrollment
*P-value of one-way ANOVA test for log payment
**P-value of Kruskal-Wallis test for log payment
***Statistically significant at =0.05 level

The mean 90-day PCI episode payments varied by patient factors, including health
plan, insurance type, readmission stage, and certain comorbidities (see Table 9). There was a
statistically significant difference between the mean 90-day PCI episode payment for
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Medicare Advantage and commercial patients (p <0.0001). Furthermore, the mean 90-day
PCI episode payments were not all the same among the readmission stages (p <0.0001). For
comorbidities, there was a statistically significant difference between the mean 90-day PCI
episode payment for patients with prior congestive heart failure and patients without (p
<.0001), for patients with prior peripheral vascular disease and patients without (p =0.0004),
and for patients with prior cerebrovascular disease and patients without (p =0.03). Also there
was a statistically significant difference between the mean 90-day PCI episode payment for
patients with prior peptic ulcer disease and patients without (p =0.05), for patients with prior
mild liver disease and patients without (p <.0001), for patients with prior diabetes with
chronic complications and patients without (p =0.004), and for patients with prior renal
disease and patients without (p <.0001). Finally, there was a statistically significant
difference between the mean 90-day PCI episode payment for patients with any malignancy,
including lymphoma and leukemia, except malignant neoplasm of the skin and patients
without (p =0.015), and for patients with metastatic solid tumor and patients without (p
=0.014).
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Table 9: PCI Episode Payments in 2018 Dollars by Patient Characteristics, Texas 2014–2018
Variable
All

Mean (SD)
$53,841 ($44,604)

Median (IQR)
$39,376 ($ 35,873)

P-Value*

Gender

Male
Female

$53,733
$54,195

($44,585)
($44,699)

$38,931
$40,349

($35,812)
($36,028)

0.96

Health Plan

$55,308
$46,561
$55,236

($45,376)
($39,807)
($45,266)

$40,185
$33,482
$40,184

($36,297)
($30,390)
($36,296)

<.0001**

Insurance

POS
PPO
Commercial

Readmission stage

Medicare Advantage
No Readmission

$46,590
$46,625

($40,267)
($35,792)

$33,223
$36,474

($30,132)
($28,029)

Within 30-D
Within 31-D to 60-D
Within 61-D to 90-D

$85,236
$100,411
$103,930

($59,283)
($64,511)
($68,351)

$67,939
$80,226
$85,145

($55,837)
(85,595)
($78,926)

Myocardial infarction

$58,691

($52,194)

$40,779

($44,678)

0.63

Congestive heart failure

$72,156

($62,072)

$49,651

($62,700)

<.0001**

Peripheral vascular disease
Cerebrovascular disease
Dementia

$68,916
$64,260
$49,816

($60,266)
($57,407)
($44,204)

$47,789
$43,683
$34,396

($56,827)
($48,097)
($33,707)

0.0004**
0.03**
0.15

Chronic pulmonary disease

$60,550

($52,830)

$43,216

($45,789)

0.09

Rheumatologic disease

$65,068

($56,269)

$43,994

($55,355)

Peptic ulcer disease
Mild liver disease
Diabetes without chronic
complications
Diabetes with chronic
complications
Hemiplegia or paraplegia
Renal disease
Any malignancy, including
lymphoma and leukemia, except
malignant neoplasm of skin
Moderate or severe liver disease
Metastatic solid tumor
AIDS/HIV

$82,484
$71,708
$56,094

($58,545)
($61,422)
($46,359)

$81,335
$47,257
$39,802

($101,178)
($55,971)
($37,993)

0.05**
<.0001**
0.23

$78,731

($66,099)

$56,955

($62,521)

<.0001**

$54,327
$81,124
$66,001

($51,297)
($66,287)
($54,397)

$41,068
$58,562
$50,178

($57,521)
($76,429)
($47,917)

0.34
<.0001**
0.0004**

$82,350
$74,911
$90,115

($76,950)
($60,628)
($98,865)

$53,925
$59,250
$44,687

($43,839)
($59,114)
($181,401)

0.11
0.014**
0.42

Comorbidities

<.0001**
<.0001**

0.12

* p value was calculated for log payment
**Statistically significant at =0.05 level

The mean 90-day PCI episode payments were calculated across patient regions. The
p-value of the ANOVA test that was performed to test log transformed PCI payments among
patient regions was significant (p <0.0001) (see Table 10). Therefore, the results showed the
patient regions of Texas were not all the same for the 90-day PCI episode payments.
Furthermore, the p-value of the Kruskal-Wallis test for PCI episode payments was significant
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(p = 0.001), so there was sufficient evidence that the median 90-day PCI episode payment for
insured patients from at least one of the regions was different than those for insured patients
from the other regions. Thus, the median payments of the 22 regions were not equal.
Table 10: Variability in the 90-day PCI Episode Payments Among Patient Regions in Texas.
Regions Ordered from the Lowest to the Highest Mean Episode Payment, Texas 2014–2018
Region
All

Mean (SD)
$53,842

P value*

($44,604)
<.0001***

Median (IQR)
$39,376

($35,873)

$45,316

($56,930)

San Angelo

$68,812

($61,259)

Fort Worth

$57,760

($43,520)

$43,888

($35,834)

Dallas

$57,438

($46,984)

$41,371

($38,690)

Longview

$57,075

($58,198)

$34,273

($39,733)

Lubbock

$56,592

($54,973)

$31,186

($55,116)

Tyler

$55,528

($41,166)

$41,471

($48,216)

Houston

$55,398

($47,203)

$39,677

($35,070)

San Antonio

$55,304

($47,738)

$38,241

($39,451)

Bryan

$53,271

($41,225)

$38,881

($47,204)

Amarillo

$52,873

($33,400)

$44,787

($39,009)

El Paso

$50,532

($28,079)

$41,936

($31,712)

Abilene

$50,031

($41,692)

$34,798

($35,934)

Austin

$48,897

($39,170)

$38,139

($30,596)

Victoria

$47,649

($30,364)

$39,311

($31,177)

Temple

$47,242

($38,119)

$34,449

($32,719)

Beaumont

$45,346

($35,234)

$30,835

($34,497)

Waco

$44,971

($45,980)

$32,761

($24,900)

Harlingen

$43,893

($31,219)

$36,139

($38,990)

Odessa

$43,693

($27,789)

$37,204

($31,732)

McAllen

$40,515

($24,192)

$29,597

($22,464)

Corpus Christi

$36,919

($24,463)

$32,854

($23,281)

P value**

<.0001***

Wichita Falls
$27,283 ($9,871)
$24,957 ($15,892)
Note: Regions ordered from the lowest to the highest mean episode payment; regions were identified
according to patients 5-digit zip codes at enrollment
*P-value of one-way ANOVA test for log payment
**P-value of Kruskal-Wallis test for log payment
***Statistically significant at =0.05 level
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Correlation Coefficient Test Statistics
Correlation coefficients were calculated between the dependent variables (i.e., 90-day
CABG episode payments and 90-day PCI episode payment) and each of the independent
continuous variables. Length of stay had a statistically significant positive and moderate
linear relationships with 90-day episode payments for both CABG surgeries and PCI
procedures (0.38 vs. 0.36, p <0.0001), meaning episode payments and length of stay tend to
increase together. On the other hand, age had a statistically significant negative and weak
linear relationship with 90-day episode payment for CABG surgeries ( -0.21, p <0.0001) but
an insufficient correlation with PCI procedures (r <0.1). CCI score had a statistically
significant weak and positive relationship with 90-day episode payments only for PCI
procedures (r =0.17, p <0.0001) and had non-significant relationship with episode payments
for CABG surgeries (p >0.05).
In addition, this study diagnosed relationship by calculating phi correlation
coefficients to perform comparisons between the type of insurance and health plan variables
(see Table 11). Upon inspection of the phi coefficient results, a strong collinearity ( =0.9826
, p <0.001) was found between the type of insurance product (i.e., commercial, Medicare
Advantage) and the health plan (i.e., PPO, POS) for CABG episodes. A strong collinearity (
=0.9773 , p <0.001) was also found between the type of business the insurance product
intended to serve and the health plan for PCI episodes. Furthermore, a strong collinearity was
found ( =0.9788 , p <0.001) by combining all CABG and PCI episodes. As a result, there
was a strong relationship between type of insurance and health plans. It was more likely that
a Medicare Advantage patient had a PPO health plan than a POS plan. Also, it was more
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likely that a commercial insurance patient had a POS health plan than a PPO health plan.
Thus, one of these two variables needed to be removed from the LASSO selection technique
to ensure the stability of the analysis. Accordingly, the health plan variable was removed.
Table 11: Distribution of Health Plans according to the Type of Business the Health
Insurance Product Intended to Serve (i.e., Medicare Advantage, Commercial)
Type of Insurance
Health Plan

Commerc
ial
n (%)

Medicare
Advantage
n ( %)

Total

P value

CABG Episodes
824 (%)
0 (0%)
824
<.0001**
POS
5 (%)
170 (%)
175
PPO
829
170
999
Total
PCI Episodes
2240 (%)
0 (%)
2240
<.0001**
POS
17 (%)
434 (%)
451
PPO
2257
434
2691
Total
All Episodes
3064 (%)
0 (%)
3064
<.0001**
POS
22 (%)
604 (%)
626
PPO
3086
604
3690
Total
Note: the comparison was performed using chi-square, and phi coefficient tests
**Statistically significant at =0.05 level

Phi Coefficient
()
0.9826

0.9773

0.9788

Furthermore, the correlation between DRG intensity and patient comorbidities was
inspected for CABG episodes (see Table 12). The results showed there was no significant
evidence for collinearity for most comorbid conditions with the DRG intensity. However,
there was a minor collinearity for a few comorbid conditions with the DRG intensity. There
was a very weak collinearity between DRG intensity and myocardial infarction ( =0.1, p
=0.0011), congestive heart failure ( =0.11, p =0.0008), and renal disease ( =0.13, p
<0.0001). Consequently, none of these variables needed to be removed from the LASSO
selection procedure for the regression model of CABG episodes.
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Table 12: Distribution of Comorbidities according to CABG DRG Intensity for CABG
Episodes
Comorbidities
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Rheumatologic disease
Peptic ulcer disease
Mild liver disease
Diabetes without chronic complications
Diabetes with chronic complications
Hemiplegia or paraplegia
Renal disease
Any malignancy, including lymphoma and
leukemia, except malignant neoplasm of skin
Moderate or severe liver disease
Metastatic solid tumor
AIDS/HIV

CABG DRG Intensity
No
Yes
n
n
506
267
121
105
550
297
77
75
555
314
72
58
500
303
127
69
622
372
5
0
539
306
88
66
612
364
15
8
624
370
3
2
598
357
29
15
468
277
159
95
541
300
86
72
626
369
1
3
582
316
45
56
593
352
34
20
625
372
2
0
621
369
6
3
626
372
1
0

Condition
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence
Absence
Presence

Total

P value

773
226
847
152
869
130
803
196
994
5
845
154
976
23
994
5
955
44
745
254
841
158
995
4
898
101
945
54
997
2
990
9
998
1

0.0011**

Phi
Coefficient
()
0.1032

0.0008**

0.1061

0.0621

0.059

0.5114

-0.0208

0.0842

-0.0546

0.1167

0.0496

0.8054

-0.0078

0.8981

0.0041

0.6588

-0.014

0.95

0.002

0.0182**

0.0747

0.1175

0.0495

<.0001**

0.1263

0.975

-0.001

0.2755

-0.0345

0.8077

-0.0077

0.4409

-0.0244

**Statistically significant at =0.05 level

Statistical Tests for Normality and Data Transformation
As shown in Figures 5 and 6, the distributions and probability plot for the 90-day
payments were positively skewed for both CAGB and PCI episodes. By checking the
distribution plot graphs and the QQ plot of log transformed payment variables, the
transformation results were found to be satisfactory as they were normally distributed.
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Figure 5: Assumption of Normality and the Log Transformation of CABG Episode Payments
CABG Episode Payments

Log Transformation of CABG Episode
Payments

Note: totalpmt = 90-day episode payment; logpmt = log transformed 90-day episode payment
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Figure 6: Assumption of Normality and the Log Transformation of PCI Episode Payments
PCI Episode Payment

Log Transformation of PCI Episode Payment

Note: totalpmt= 90-day episode payment.; logpmt=log transformed 90-day episode payment
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Independent Predictors of 90-Day Episode Payments
Table 13 showed the results of the LASSO performed on the independent variables
for each of the three primary outcome variables, which were the 90-day CABG episode
payment, the 90-day PCI episode payment, and the 90-day episode payment of all CABG and
PCI episodes combined. The LASSO analysis resulted in small sets of variables of interest,
with each set including fifteen variables. Within each set of variables, all the fifteen variables
were included in the regression models. Three multiple linear regression models were used to
examine the associations between patient factors and the 90-day episode payments for CABG
surgeries, PCI procedures, and all CABG and PCI episodes combined.
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Table 13: LASSO Selection Summary for Episode Payments

0
1
2
3
4

CABG Episodes
Effect Entered
Model
RSquare
Intercept
0
Length of Stay
0.0575
within 30-D
0.1135
Age
0.1787
within 31-D to 60-D
0.1826

Adjusted
RSquare
0
0.0565
0.1117
0.1763
0.1793

PCI Episodes
Effect Entered
Model
RSquare
Intercept
0
Length of Stay
0.0481
within 31-D to 60-D
0.0532
within 30-D
0.1391
within 61-D to 90-D
0.1675

5

Austin

0.2107

0.2067

Medicare Advantage

0.2155

0.2141

6

DRG Intensity

0.2296

0.2249

Renal disease

0.2174

0.2156

7

within 61-D to 90-D

0.2327

0.2273

Diabetes with chronic
complications

0.2469

0.2449

8
9

0.3322
0.3438

0.3268
0.3378

Age
Corpus Christi

0.2475
0.2625

10
11
12
13

Medicare Advantage
Diabetes with chronic
complications
Fort Worth
Peripheral vascular disease
Cerebrovascular disease
Dallas

0.3456
0.3506
0.3596
0.3601

0.3389
0.3434
0.3518
0.3516

14

Congestive heart failure

0.361

0.3519

Fort Worth
Dallas
Austin
Any malignancy, including
lymphoma and leukemia,
except malignant neoplasm
of skin
Mild liver disease

0.3627

0.3530*

Diabetes without chronic
complications

Step

15

Any malignancy, including
lymphoma and leukemia,
except malignant neoplasm
of skin
*Optimal value of criterion
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All Episodes
Model RSquare

Adjusted
R-Square

Effect Entered

Adjusted RSquare

0
0.0477
0.0525
0.1381
0.1662

0
0.1377
0.1405
0.1725
0.2282

0
0.1375
0.14
0.1718
0.2274

0.24

0.239

0.3038

0.3027

0.3133

0.312

0.2453
0.26

Intercept
Length of Stay
within 30-D
CABG Surgery
within 31-D to
60-D
within 61-D to
90-D
Medicare
Advantage
Diabetes with
chronic
complications
Age
Renal disease

0.3243
0.3301

0.3228
0.3285

0.2641
0.266
0.2673
0.2693

0.2614
0.263
0.264
0.2657

Austin
Corpus Christi
Fort Worth
Dallas

0.3459
0.346
0.3497
0.3536

0.3441
0.3441
0.3476
0.3513

0.2726

0.2688

0.355

0.3525

0.2747

0.2707*

Mild liver
disease
Metastatic solid
tumor

0.3572

0.3546*

For the first regression model (see Table 14), the predictor variables explained
37.11% of the variation in the values of 90-day CABG episode payments (R2 =0.3711). By
reviewing the tolerance and variance inflection values, there were no tolerance values that
fell below 0.1 and there were no variance inflation values above the value of 10. As a result,
there was no threat of multicollinearity indicated through the tolerance and variance inflation
analyses. After controlling for all other variables, episode payments were 22.78% lower for
Austin region patients than those for Houston region patients (p <0.0001). For every one-year
increase in age, episode payments decreased by 1.25 % (p <0.0001). Episode payments were
16.58% lower for Medicare Advantage patients than those for commercial patients (p
<0.0001). Episode payments were 9.99% higher for patients with peripheral vascular disease
than for other patients (p =0.0309). Episode payments were 7.04% lower for patients with
cerebrovascular disease than for other patients (p =0.0479). Episode payments were 8.87%
higher for patients who had intense DRGs (i.e., 231, 233, 235) at the time of index
hospitalization than those for other patients (p =0.0051). For a one-day increase in length of
stay, total episode payments increased by 4.30 % (p <0.0001). Episode payments for
readmitted patients within 30-days, within 31-60-days, and within 61- 90-days were higher
than those for non-readmitted patients by 55.08%, 37.77%, and 39.93%, respectively (p
<0.0001). The remaining independent variables in the model had non-significant p values (p
>0.05).
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Table 14: Linear Regression Model of Predictors of Episode Payments for CABG Procedures
Variable
Intercept

Coefficient

SE

t value

Tolerance

VI

P Value

11.5178

0.11352

101.46

.

0

<.0001

Exponentiated Estimate*

Texas regions
Houston

Reference

Austin

-0.2585

0.04591

-5.63

0.84286

1.18644

<.0001**

-22.78%

Dallas

0.04211

0.03757

1.12

0.80416

1.24353

0.2626

4.30%

Fort Worth

0.09129

0.04876

1.87

0.87034

1.14897

0.0615

9.56%

Other Regions

-0.0016

0.03894

-0.04

0.78556

1.27297

0.9672

-0.16%

-0.01256

0.00188

-6.69

0.70909

1.41026

<.0001**

-1.25%

1.43374

<.0001**

-16.58%
3.56%

Age
Type of insurance
Commercial Insurance

Reference

Medicare Advantage

-0.18134

0.04351

-4.17

0.69748

Congestive heart failure

0.03502

0.03957

0.89

0.92302

1.0834

0.3763

Peripheral vascular disease

0.09524

0.04405

2.16

0.84866

1.17832

0.0309**

9.99%

Cerebrovascular disease

-0.07299

0.03685

-1.98

0.87075

1.14844

0.0479**

-7.04%

Diabetes with chronic complications
Any malignancy, including lymphoma and
leukemia, except malignant neoplasm of skin

0.06266

0.03888

1.61

0.92644

1.0794

0.1073

6.47%

-0.0719

0.06092

-1.18

0.98237

1.01795

0.2382

-6.94%

0.08498

0.0303

2.81

0.86913

1.15058

0.0051**

8.87%

0.04208

0.00333

12.63

0.85485

1.16979

<.0001**

4.30%

0.0498

8.81

0.94564

1.05748

<.0001**

55.08%

DRG Intensity
No (without MCC)
Yes (with MCC)
Length of Stay
Readmission Stage
No Readmission

Reference

Reference

within 30-D

0.43878

within 31-D to 60-D

0.32044

0.0688

4.66

0.93546

1.069

<.0001**

37.77%

within 61-D to 90-D

0.32878

0.07617

4.32

0.95047

1.05211

<.0001**

38.93%

n= 999; R-Square: 0.3711; Adj R-Square: 0.3608; F-value: 36.21; P < 0.0001; VI, variance inflation; DRG, Diagnosis Related Groups
* Exponentiated parameter estimates (EXP(Coefficient)-1) *100,
**Statistically significant at =0.05 level
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For the second regression model (see Table 15), the predictor variables explained
27.92% of the variation in the values of 90-day PCI episode payments (R2 = 0.2792). There
were no tolerance values that fell below 0.1 and there were no variance inflation values
above the value of 10. As a result, there was no threat of multicollinearity indicated through
the tolerance and variance inflation analyses. After controlling for all other variables, episode
payments were 20.76% lower for Corpus Christi region patients than those for Houston
region patients (p=0. 0017). Alternatively, episode payments for Fort Worth patients were
8.55% higher than episode payments for Houston region patients (p=0. 0297). For every oneyear increase in age, episode payments decreased by 0.33% (p=0.0092). Episode payments
were 26.4% lower for Medicare Advantage patients than those for commercial patients (p
<0.0001). Episode payments were 15.77% higher for patients with diabetes with chronic
complications than for other patients (p=0. 0008). Episode payments were 18.04% higher for
patients with renal disease than for other patients (p=0.0002). For a one-day increase in
length of stay, episode payments increased by 4.89% (p <0.0001). Episode payments for
readmitted patients within 30-days, within 31-60-days, and within 61-90-days were higher
than for non-readmitted patients by 69.05%, 62.96%, and 68.07%, respectively (p <0.0001).
The remaining independent variables in the model had non-significant p values (p >0.05).
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Table 15: Linear Regression Model of Predictors of Episode Payments for PCI Procedures
Variable
Intercept

Coefficient

SE

t value

Tolerance

VI

P Value

10.58289

0.07282

145.33

.

0

<.0001

Exponentiated Estimate*

Texas Regions
Houston

Reference

Austin

-0.0584

0.03856

-1.51

0.92877

1.07669

0.13

-5.67%

Corpus Christi

-0.23275

0.07395

-3.15

0.97681

1.02374

0.0017**

-20.76%

Dallas

0.05851

0.03058

1.91

0.90492

1.10507

0.0558

6.03%

0.08204

0.03772

2.18

0.93079

1.07435

0.0297**

8.55%

-0.00329

0.00126

-2.61

0.69121

1.44674

0.0092**

-0.33%

Fort Worth
Age
Type of Insurance
Commercial Insurance

Reference

Medicare Advantage

-0.30656

0.03754

-8.17

0.69009

1.44908

<.0001**

-26.40%

0.05958

0.05832

1.02

0.96162

1.03992

0.3071

6.14%

0.04648

0.02974

1.56

0.96259

1.03887

0.1182

4.76%

0.14646

0.04372

3.35

0.83461

1.19817

0.0008**

15.77%

0.16584

0.04454

3.72

0.84496

1.18349

0.0002**

18.04%

0.08409

0.05317

1.58

0.94988

1.05276

0.1139

8.77%

0.04771

0.00272

17.54

0.94499

1.05821

<.0001**

4.89%

Mild liver disease
Diabetes without chronic complications
Diabetes with chronic complications
Renal disease
Any malignancy, including lymphoma and
leukemia, except malignant neoplasm of skin
Length of Stay
Readmission Stage
No Readmission
within 30-D

Reference
0.525

0.04135

12.7

0.95816

1.04366

<.0001**

69.05%

within 31-D to 60-D

0.48834

0.05324

9.17

0.90443

1.10566

<.0001**

62.96%

within 61-D to 90-D

0.5192

0.06218

8.35

0.93298

1.07183

<.0001**

68.07%

n= 2,691; R-Square: 0.2792; Adj R-Square: 0.2752; F-value: 69.09; P < 0.0001; VI, variance inflation;
* Exponentiated parameter estimates (EXP(Coefficient)-1) *100,
**Statistically significant at =0.05 level
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For the next regression model (see Table 16), the predictor variables explained
36.24% of the variation in the values of 90-day episode payments for both CABG and PCI
procedures (R2 = 0.3624). There were no tolerance values that fell below 0.1 and there were
no variance inflation values above the value of 10. As a result, there was no threat of
multicollinearity indicated through the tolerance and variance inflation analyses. After
controlling for all other variables, the model demonstrated that the 90-day episode payments
were 34.63% higher for CABG episode patients than those for PCI episode patients (p
<0.0001). Total episode payments were 11.49% lower for Austin region patients than those
for Houston region patients (p <0.0001). Total episode payments were 13.28% lower for
Corpus Christi region patients than those for Houston region patients (p =0.0086). Total
episode payments were 4.99% higher for Dallas region patients than those for Houston
region patients (p =0.046). Total episode payments were 8.02% higher for Fort Worth region
patients than those for Houston region patients (p =0.0119). For every one-year increase in
age, episode payments decreased by 4.8% (p <0.0001). Total episode payments were 24.13%
lower for Medicare Advantage patients than for commercial patients (p <0.0001). Total
episode payments were 12.13% higher for patients with diabetes with chronic complications
than for other patients (p =0.0004). Total episode payments were 13.07% higher for patients
with renal disease than those for patients without renal disease (p =0.0005). For a one-day
increase in length of stay, total episode payments increased by 4.85 % (p <0.0001). Episode
payments for readmitted patients within 30-days, 31-60-days, and 61-90-days were higher
than for non-readmitted patients by 65.17%, 57.26%, and 61.74%, respectively (p <0.0001).
The remaining independent variables in the model had non-significant p values (p >0.05).
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Table 16: Linear Regression Model of Predictors of Episode Payments for Coronary Revascularization Procedures, CABG and
PCI procedures
Variable
Intercept
Revascularization Procedure
PCI Procedure
CABG Surgery

Coefficient

SE

t value

Tolerance

VI

P Value

Exponentiated Estimate*

10.69608

0.0611

175.05

.

0

<.0001

0.02365

12.57

0.76777

1.30247

<.0001**

34.63%

Reference
0.29733

Texas Regions
Houston

Reference

Austin

-0.12201

0.03063

-3.98

0.92322

1.08317

<.0001**

-11.49%

Corpus Christi

-0.14249

0.0542

-2.63

0.97239

1.0284

0.0086**

-13.28%

Dallas

0.0487

0.0244

2

0.90243

1.10812

0.046**

4.99%

Fort Worth

0.07717

0.03066

2.52

0.93123

1.07385

0.0119**

8.02%

-0.00477

0.00105

-4.53

0.70309

1.42228

<.0001**

-0.48%

Age
Type of Insurance
Commercial Insurance

Reference

Medicare Advantage

-0.27616

0.02973

-9.29

0.70091

1.42671

<.0001**

-24.13%

Mild liver disease

0.06628

0.04608

1.44

0.98047

1.01992

0.1504

6.85%

Diabetes with chronic complications

0.11451

0.03205

3.57

0.85064

1.17558

0.0004**

12.13%

Renal disease

0.12288

0.03508

3.5

0.84169

1.18809

0.0005**

13.07%

Metastatic solid tumor

0.16273

0.09275

1.75

0.99313

1.00692

0.0794

17.67%

Length of Stay

0.04735

0.00216

21.92

0.75344

1.32725

<.0001**

4.85%

Readmission Stage
No Readmission

Reference

within 30-D

0.5018

0.03318

15.12

0.96173

1.0398

<.0001**

65.17%

within 31-D to 60-D

0.45273

0.04356

10.39

0.91512

1.09275

<.0001**

57.26%

within 61-D to 90-D

0.48085

0.05013

9.59

0.94413

1.05918

<.0001**

61.74%

n= 3,690; R-Square: 0.3624; Adj R-Square: 0.3598; F-value: 139.19; P < 0.0001; VI, variance inflation;
* Exponentiated parameter estimates (EXP(Coefficient)-1) *100,
**Statistically significant at =0.05 level
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This study further explored the readmission rates across main Texas regions for both
CABG and PCI episodes (see Table 17). Readmission rates differed notably among patient
regions. For CABG episodes across Texas, San Antonio had the lowest readmission rate
(6.94%), while the category of Other Regions categories had the highest readmission rate
(17.01%), followed by Dallas region (16.43%) (see Figure 7). For PCI episodes, Corpus
Christi had the lowest readmission rate (8.82%), while Fort Worth had the highest
readmission rate (16.94%).
Table 17: 90-day Readmissions Rates, CABG and PCI Episodes
Region

Total
Episodes

90-day CABG Episodes
Number of
Readmission
Readmissions
Rate

Total
Episodes

90-day PCI Episodes
Number of
Readmission
Readmissions
Rate

Austin

119

9

7.56%

287

33

11.50%

Corpus Christi

45

5

11.11%

68

6

8.82%

Dallas

207

34

16.43%

518

84

16.22%

Fort Worth

100

15

15.00%

301

51

16.94%

Houston

262

38

14.50%

670

105

15.67%

San Antonio

72

5

6.94%

273

43

15.75%

Other Regions

194

33

17.01%

574

86

14.98%

Total

999

139

13.91%

2691

408

15.16%
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Figure 7: Readmission Rates by Patient Regions
18.00%
16.43%

17.01%

16.94%

16.22%

15.75%

15.67%

16.00%
15.00%

14.98%

14.50%

14.00%
11.50%

12.00%

11.11%

10.00%
8.82%

8.00%

7.56%
6.94%

6.00%
4.00%
2.00%

0.00%
Austin

Corpus Christi

Dallas

Fort Worth

CABG

Houston

San Antonio

Other Regions

PCI

Note: Other regions: Abilene, Amarillo, Beaumont, Bryan, El Paso, Harlingen, Longview, Lubbock, McAllen, Odessa, San Angelo, Temple, Tyler, Victoria, Waco, and Wichita Falls;
All regions were identified according to patients 5-digit zip codes at enrollment.
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This study also identified the five most common causes for 90-day readmissions for
both CABG surgeries and PCI procedures by detecting the DRG codes used for readmissions
(see Table 18). As shown in Table 18, the most common cause of CABG 90-day episode
readmissions according the MS-DRG codes was DRG 857(4.71%), followed by DRG 603
(3.66%), DRG 291 (3.14%), DRG 293 (2.62%), and DRG 863 (2.62%). Alternatively, the
most common causes of PCI 90-day episode readmissions according to the MS-DRG codes
was DRG 247(8.63%), followed by DRG 287 (4.75%), DRG 291(4.40%), DRG 246
(3.70%), and DRG 236 (3.35%) (see Table 18).
Moreover, the five most common principal diagnoses (i.e., first field diagnoses) were
identified based on the ICD9 and ICD10 coding systems for all causes of 90-day
readmissions for CABG and PCI episodes (see Table 19). As shown in Table 19,the most
common cause of CABG 90-day episode readmission was ICD9 code 99859 (5.15%),
followed by ICD10 code T814XXA (5.15%), ICD10 code I214 (3.09%), ICD10 code J90
(3.09%), and ICD10 code I2699 (2.06%). The most common cause of PCI 90-day episode
readmission was ICD10 code I214 (5.72%), followed by ICD10 code I25110 (5.37%),
ICD10 code I2510 (5.20%), ICD10 code 41401 (4.85%), and ICD10 code I110 (1.91%).
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Table 18: Most Common Causes of 90-day Readmissions of CABG and PCI Episodes, MS-DRGs
CAGB Episodes
Percentage
4.71%

Code
857

3.66%

603

DRG Description
Postoperative & Post-Traumatic Infections with O.R.
Procedure with CC

PCI Episodes
Percentage
8.63%

Code
247

4.75%

287

Cellulitis without MCC

DRG Description
Percutaneous Cardiovascular Procedures with Drug-eluting
Stent without MCC

Circulatory Disorders Except AMI, with Cardiac
Catheterization without MCC
3.14%
291
Heart Failure and Shock with MCC OR Peripheral
4.40%
291
Heart Failure and Shock with MCC OR Peripheral
Extracorporeal Membrane Oxygenation (ECMO)
Extracorporeal Membrane Oxygenation (ECMO)
2.62%
293
Heart Failure and Shock without CC/MCC
3.70%
246
Percutaneous Cardiovascular Procedures with Drug-eluting
Stent with MCC or 4+ Vessels or Stents
2.62%
863
Postoperative & Post-Traumatic Infections without
3.35%
236
Coronary Bypass without Cardiac Catheterization without
MCC
MCC
CC, complication or comorbidity; MCC, major complication or comorbidity; MS-DRG, Medicare severity diagnosis-related group

Table 19: Most Common Principal Diagnoses of 90-day Readmissions of CABG and PCI episodes, ICD9 and ICD10
CAGB Episodes
Percentage
5.15%
5.15%

Code
99859
T814XXA

3.09%

I214

3.09%
2.06%

J90
I2699

Description
Other postoperative infection
Infection following a procedure, initial encounter

PCI Episodes
Percentage
5.72%
5.37%

Code
I214
I25110

Non-ST elevation (NSTEMI) myocardial infarction

5.20%

I2510

Pleural effusion, not elsewhere classified
Other pulmonary embolism without acute cor
pulmonale

4.85%
1.91%

41401
I110
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Description
Non-ST elevation (NSTEMI) myocardial infarction
Atherosclerotic heart disease of native coronary artery with
unstable angina pectoris
Atherosclerotic heart disease of native coronary artery
without angina pectoris
Coronary atherosclerosis of native coronary artery
Hypertensive heart disease with heart failure

Drivers of 90-Day Episode Payment Variations at the Hospital Level
For CABG surgeries at the hospital level, 709 episodes performed in 64 hospitals
across the state of Texas were identified after excluding episodes in hospitals with less than
five episodes performed over the study period (see Table 20). Payment variation between
high- and low- payment hospitals were considerable. The mean 90-day CABG episode
payment for hospitals was $61,028 in the lowest payment quartile of spending vs. $106,148
in the highest quartile, for a difference of $45,121 (74%). Payments for index procedure
accounted for the largest share of total episode payment for CABG surgeries, ranging from
56% to 62% across quartiles.
All payment components for 90-day CABG episodes were higher in payments for the
high-payment quartile than those for the low-payment quartile except for pharmacy (see
Figure 9). In comparison to with the lowest payment quartile hospitals, the highest payment
quartile hospitals had 58% higher index procedure payments ($59,851 vs. $37,946), 55%
higher professional payments ($21,955 vs. $14,179), 105% higher post-acute-care payments
($12,859 vs. $6,259), 796% higher readmission payments ($10,069 vs. $1,124), and 7%
lower pharmacy payments ($1,414 vs. $1,519). Thus, payment difference between high- and
low- payment hospitals for 90-day CABG episode payments was greatest for readmission
payments, followed by post-acute care payments, index procedure payments, professional
payments, and pharmacy payments. Thus, the study showed that the component with the
highest difference rate between high- and low-payment hospitals was related to readmission
(see Figure 14).
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Within professional service payments, payments for surgery accounted for the
majority of payments across quartiles. Within post-acute care payments, payments for
“outpatient facility surgery” accounted for a significant proportion of payments and was a
key driver 6.2% of payment variation (see Table 20). Readmission rates for 90-day CABG
episodes differed significantly between low- and high-payment hospitals (8.90% for lowpayment hospitals vs. 14.92% for high-payment hospitals).
As for the drivers of these differences, index procedure contributed 48.6% to the
variation in total episode payments between high-payment and low-payment hospitals.
Readmission, professional service, post-acute care, and pharmacy contributed to the variation
in total episode payments between high-payment and low-payment hospitals by 19.8%,
17.2%, 14.6%, and 0.23%, respectively (see Figure 9). Finally, for the five hospitals with the
highest total 90-day CABG episode payments, the component that drove the higher payment
varied from hospital to hospital (see Table 21).
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Table 20: The Contribution of CABG Payment Components and Subcomponents to Total
Episode Payment Variation between High- and Low-payment Hospitals

4 (Highest)

Difference
between
Lowest and
Highest Cost
Quartiles**
$

Pharmacy

$1,349

$1,519

$1,414

$105

0.23%

Readmissions

$5,220

$1,124

$10,069

$8,945

19.82%

$427

$263

$671

$408

0.90%

$1,142

$869

$1,214

$345

0.76%

$597

$849

$615

$235

0.52%

$1,278

$306

$3,133

$2,828

6.27%

OP Facility Radiology

$259

$180

$180

-

0.00%

OP Facility Laboratory

$190

$123

$169

$ 45

0.10%

OP Facility Diagnostic

$298

$402

$263

$140

0.31%

Emergency Room

$1,565

$1,432

$1,616

$184

0.41%

OP Facility Other

$3,372

$1,835

$4,999

$3,164

7.01%

Subtotal Post-acute Care
E&M

$9,128
$3,225

$6,259
$2,327

$12,859
$4,191

$6,600
$1,864

14.63%
4.13%

Anesthesia

$5,776

$4,710

$7,099

$2,389

5.29%

Laboratory

$139

$93

$133

$40

0.09%

Emergency Room

$241

$213

$263

$50

0.11%

Diagnostic Testing

$527

$442

$710

$268

0.59%

Physical Medicine/Rehab

$110

$137

$104

$32

0.07%

Payment
Component

Subcomponent

All
Hospitals
*

Quartiles

1 (Lowest)

Post-acute Care

Home Health
Ancillary
Rehab/Skilled Nursing Facility
OP Facility Surgery

Professional

Radiology

Variation
Attributed
to Payment
Component
%

$252

$205

$301

$96

0.21%

$7,231

$5,837

$8,834

$2,997

6.64%

$303

$215

$321

$106

0.24%

$17,803

$14,179

$21,955

$7,777

17.24%

Index Procedure

$48,886

$37,946

$59,851

$21,904

48.55%

Total

$82,387

$61,028

$106,148

$ 45,121

100.00%

Surgery
Professional Other
Subtotal Professional

*Hospitals that performed less than five episodes were excluded
**the absolute difference was calculated
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Figure 8: The Percentage of Differences between High- and Low-payment Hospitals for
CABG Episode
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Figure 9: CABG Payment Components and Variation of Average 90-Day Episode Payments among Hospital Payment Quartiles.
The Contribution of Each Component to the Total CABG Episode Payment Variation between High- and Lowpayment Hospitals
$120,000.00

100%

0.2%

90%

17%

$106,148

$100,000.00
80%

$88,625

70%

$80,000.00

20%

$73,745

60%

$61,028

15%

$60,000.00

50%
40%

$40,000.00
30%
49%
20%

$20,000.00

10%
$-

1

2

3

4

Pharmacy

$1,518.85

$1,099.27

$1,364.31

$1,413.54

Readmission

$1,124.21

$3,356.49

$6,331.83

$10,069.25

Postacute Care

$6,259.49

$7,457.03

$9,937.15

$12,859.23

Professional Services

$14,178.54

$16,478.70

$18,599.63

$21,955.45

Index Hospitalization

$37,946.49

$45,353.99

$52,392.56

$59,850.87
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0%
Variation

Pharmacy
Professional Services
Readmission
Postacute Care
Index Procedure

Table 21: CABG Episode Payment Components of Lowest Quartile Hospitals, Highest
Quartile Hospitals, and the 5 Hospitals with the Highest CABG Episode Payments, Texas
2014-2018
Average Payment
Payment

Lowest

Highest

Component

Quartile

Quartile

Hospitals

Hospitals

Hospital A

Hospital B

Hospital C

Hospital D

Hospital E

Pharmacy

$1,519

$1,414

$1,748

$1,564

$1,336

$1,938

$819

Readmission

$1,124

$10,069

$21,532

$43

-

$34,359

-

Post-acute Care

$6,259

$12,859

$5,595

$23,142

$5,519

$6,088

$16,207

Professional

$14,179

$21,955

$17,580

$26,536

$27,081

$19,939

$22,738

Index

$37,946

$59,851

$80,514

$72,833

$79,836

$50,271

$70,081

Total Episode

$61,028

$106,148

$126,967

$124,118

$113,772

$112,594

$109,844
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For PCI procedures at the hospital level, 2,132 episodes performed in 146 hospitals
across the state of Texas were identified after excluding episodes of hospitals with less than
five episodes preformed over the study period (see Table 22). Payment variations between
high- and low-payment hospitals were considerable. The mean 90-day PCI episode payment
for hospitals was $33,696 in the lowest payment quartile of spending vs. $74,510 in the
highest quartile, for a difference of $40,814 (121%). Payments for index procedure
accounted for the largest share of total PCI episode payment ranging from 47% to 60%
across quartiles.
All payment components for PCI episodes were higher in payments for hospitals in
the high-payment than those for the low-payment quartile (see Figure 10). In comparison to
the lowest payment quartile hospitals, the highest payment quartile hospitals had 75% higher
index procedure payments ($35,201 vs. $20,137), 46% higher professional payments ($7,774
vs. $5,308), 271% higher post-acute care payments ($20,023 vs. $5,402), 539% higher
readmission payments ($9,879 vs. $1,546), and 25% higher pharmacy payments ($1,633 vs.
$1,303). As a result, payment difference between high- and low- payment hospitals for 90day PCI episode payments was greatest for readmission payments, followed by post-acute
care payments, index procedure payments, professional payments, and pharmacy payments.
Readmission rates of 90-day PCI episodes differed significantly between low- and highpayment hospitals (9.32% for the low-payment hospitals vs. 15.30% for the high-payment
hospitals).
As for the drivers of these differences, index procedure and post-acute care
components contributed to the variation in total episode payment between high-payment and
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low-payment hospitals by about the same percentage (36.9% and 35.8%, respectively).
Readmission, professional services, and pharmacy contributed to the variation in total
episode payments between high-payment and low- payment hospitals by 20.4%, 6%, and
0.81%, respectively (see Figure 11). Finally, among the five hospitals with the highest total
PCI episode payments, the component that drove these higher payments varied from hospital
to hospital (see Table 23).
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Table 22: The Contribution of PCI Payment Components and Subcomponents to Total
Episode Payment Variation between High- and Low-payment Hospitals
Payment
Component

Subcomponent*

All
Hospitals
*

Quartiles

1
(Lowest)

4
(Highest)

Difference
between
Lowest and
Highest Cost
Quartiles**

Variation
Attributed
to Payment
Components

$

%

Pharmacy

$1,472

$1,303

$1,633

$330

0.81%

Readmissions

$4,393

$1,546

$9,879

$8,333

20.42%

$143

$76

$112

$36

0.09%

$2,883

$1,674

$5,685

$4,010

9.83%

$86

$45

$137

$92

0.23%

$3,133

$1,126

$5,496

$4,370

10.71%

OP Facility Radiology

$286

$218

$315

$96

0.24%

OP Facility Laboratory

$198

$163

$330

$167

0.41%

Post-acute Care

Home Health
Ancillary
Rehab/Skilled Nursing Facility
OP Facility Surgery

OP Facility Diagnostic

$668

$389

$601

$212

0.52%

Emergency Room

$2,041

$1,184

$3,154

$1,970

4.83%

OP Facility Other

$2,059

$525

$4,192

$3,667

8.98%

$11,496

$5,402

$ 20,023

$ 14,621

35.82%

$1,929

$1,698

$2,358

$660

1.62%

Anesthesia

$448

$243

$456

$213

0.52%

Laboratory

$148

$148

$163

$15

0.04%

Emergency Room

$407

$345

$460

$114

0.28%

Diagnostic Testing

$622

$458

$722

$264

0.65%

$22

$14

$18

$4

0.01%

$241

$166

$245

$80

0.20%

$2,651

$2,076

$3,079

$1,002

2.46%

Total Post-acute Care
Professional

E&M

Physical Medicine/Rehab
Radiology
Surgery

Index Procedure

Professional Other

$212

$161

$274

$113

0.28%

Total Professional

$6,678

$5,308

$7,774

$2,466

6.04%

Inpatient Facility

$28,316

$20,137

$35,201

$15,064

36.91%

$52,355

$33,696

$74,510

$40,814

100.00%

Total
*hospitals that performed less than five episodes were excluded.
**the absolute difference in payment was calculated
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Figure 10: The Percentage of Differences between High- and Low-payment Hospitals for
PCI Episode
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Figure 11: PCI Payment Components and Variation of Average 90-Day Episode Payments among Hospital Quartiles. The
Contribution of Each Component to the Total PCI Episode Payment Variation between High- and Low-payment
Hospitals
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1%

$74,510

90%

$70,000.00

80%
$60,000.00

70%

$50,000.00
$40,000.00

60%

$45,152

50%

$33,696

6%
20%

40%

$30,000.00

30%

$20,000.00

20%
$10,000.00

$-

36%

$56,156

37%

10%

1

2

3

4

Pharmacy

$1,302.75

$1,359.27

$1,593.74

$1,632.86

Postacute Care

$5,401.80

$8,447.91

$12,179.09

$20,022.59

Professional Services

$5,308.40

$6,458.67

$7,163.28

$7,774.30

Readmission

$1,546.36

$2,854.54

$3,361.70

$9,879.42

Index Hospitalization

$20,136.96

$26,031.96

$31,858.67

$35,200.95
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Table 23: PCI Episode Payment Components of Lowest Quartile Hospitals, Highest Quartile
Hospitals, and the 5 Hospitals with the Highest PCI Total Episode Payments, Texas 20142018
Average Payment
Payment

Lowest

Highest

Component

Quartile

Quartile

Hospitals

Hospitals

Hospital A

Hospital B

Hospital C

Hospital D

Hospital E

Pharmacy

$1,303

$1,633

$606

$1,084

$893

$2,196

$2,495

Readmission

$1,546

$9,879

$53,999

$801

$7,320

$21,558

$22,755

Post-acute Care

$5,402

$20,023

$51,235

$4,451

$41,410

$24,008

$18,235

Professional

$5,308

$7,774

$14,829

$4,719

$9,387

$7,696

$7,287

Index

$20,137

$35,201

$30,117

$97,412

$34,504

$34,266

$30,412

Total Episode

$33,696

$74,510

$150,786

$108,467

$93,514

$89,723

$81,184

Subgroup Analyses
As shown in Table 24, for the CABG episode subgroup analyses, there were 381
episodes where CABG surgery was performed for DRG type without major complication and
comorbidities and 663 episodes where CABG surgery was performed for patients with
commercial insurance. After reclassifying hospitals into payment quartiles within each
subgroup, index procedures remained the main driver of payment variation within the CABG
episode subgroups.
For the PCI episode subgroup analyses, there were 1,469 episodes where a PCI
procedure was performed for PCI with AMI and 1,952 episodes where a PCI procedure was
performed for patients with commercial insurance. After reclassifying hospitals into payment
quartiles within the two subgroups, for the AMI PCI subgroup, index procedures and postacute care were found to contribute to payment variation about the same amount. For the
commercial PCI subgroup, index procedure was the main driver of payment variation.
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Table 24: Payment Components and Variation of Average 90-Day Episode Payments for CABG and PCI Procedures between
High- and Low-Payment Hospitals in the Subgroups
Payment Component

Low Payment Hospitals

High Payment Hospitals

Difference

% Variation

DRG Intensity CABG* (n=381)
Index Procedure
Post-acute Care
Readmission
Professional Services
Pharmacy
Total Episode Payment

$35,418
$5,400
$1,399
$13,571
$1,675
$57,462

$54,385
$9,716
$3,940
$19,840
$1,268
$89,150

$18,967
$4,316
$2,541
$6,270
$407
$31,687

60%
14%
8%
20%
-1%

Commercial CABG (n=663)
Index Procedure
Post-acute Care
Readmission
Professional Services
Pharmacy
Total Episode Payment

$39,416
$5,424
$1,251
$14,794
$1,758
$62,643

$63,295
$11,857
$10,991
$ 21,399
$1,372
$108,915

$23,878
$6,434
$9,740
$6,605
$(386)
$46,272

52%
14%
21%
14%
-1%

AMI PCI (n=1,469)
Index Procedure
Post-acute Care
Readmission
Professional Services
Pharmacy
Total Episode Payment

$20,483
$5,178
$958
$5,106
$1,267
$32,992

$35,987
$20,723
$11,184
$8,146
$1,608
$77,647

$15,504
$15,545
$10,225
$3,039
$342
$44,655

35%
35%
23%
7%
1%

Commercial PCI (n=1,952)
Index Procedure
Post-acute Care
Readmission
Professional Services
Pharmacy
Total Episode Payment

$21,550
$4,750
$1,011
$5,417
$1,407
$34,136

$36,114
$19,257
$10,589
$7,756
$1,714
$75,429

$10,811
$7,250
$2,179
$1,766
$232
$22,238

49%
33%
10%
8%
1%

Note: hospitals were ranked from lowest to highest average 90-day episode payments and then categorized into low and high payment hospitals
* Index CABG hospitalization without a major complication or comorbidity
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Drivers of 90-Day Episode Payment Variations at the Regional Level
Furthermore, two Texas maps were created to demonstrate the variability of episode
payments visually across Texas regions ,which were identified according to patients 5-digit
zip codes at enrollment, for both of CABG episodes and PCI episodes (see Figures 12 & 13).
Figure 12: Texas Map with CABG Surgery Episode Payment Variation
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Figure 13: Texas Map with PCI Episode Payment Variation

For CABG surgeries at the regional level, 997 episodes were identified across Texas
HRRs, excluding the El Paso region because it had less than five episodes over the study
period (see Table 25). There was considerable payment variation between high- and lowpayment regions. The mean 90-day CABG episode payment for the identified regions was
$62,639 in the lowest payment quartile vs. $90,444 in the highest quartile, for a difference of
$27,805 (44.4%). Payments for index procedure accounted for the largest share of total
episode payment for CABG surgeries ranging from 58.33% to 65.86% across quartiles.
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All payment components for CABG episodes were higher in payments for the highpayment quartile than those for the low-payment quartile. In comparison to the lowest
payment quartile regions, the highest payment quartile regions had 35.75% higher index
procedure payments ($52,753 vs. $38,861), 39.66% higher professional payments
($17,501vs. $12,531), 12.73% higher post-acute care payments ($8,880 vs. $7,877), 312.53%
higher readmission payments ($9,961 vs. $2,415), and 41.25% higher pharmacy payments
($1,349 vs. $955). Thus, payment difference between high- and low- payment regions for 90day CABG episode payments was greatest for readmission payments.
As for the drivers of these differences, index procedure contributed 49.96% to the
variation in total episode payments between high- and low-payment regions. Readmission,
professional service, post-acute care, and pharmacy contributed to the variation in total
episode payments between high-payment and low-payment regions by 27.14%, 17.87%,
3.61%, and 1.4%, respectively (see Table 25).
Table 25: Payment Components and Variation of Average 90-Day Episode Payments for
CABG Procedures between High- and Low-Payment Regions.
Payment Component

Low Payment
Regions

High Payment
Regions

Difference*

CABG (n=997)
Index Procedure
38,861
52,753
13,892
Post-acute Care
7,877
8,880
1,003
Readmission
2,415
9,961
7,546
Professional Services
12,531
17,501
4,970
Pharmacy
955
1,349
394
Total Episode Payment
62,639
90,444
27,805
Note: El Paso region was removed because it had less than 5 episodes. Payments were estimated at regional level
. *The absolute differences between high- and low-payment regions

% Variation

49.96%
3.61%
27.14%
17.87%
1.4%

For PCI procedures at the regional level, 2,691 episodes performed in 22 HRRs
across the state of Texas were identified (see Table 26). There was no single region with
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fewer than five episodes over the study period. There was considerable payment variation
between high- and low-payment regions. The mean 90-day PCI episode payment for all
regions was $38,460 in the lowest payment quartile of spending vs. $59,535 in the highest
quartile, for a difference of $21,075 (5%). Payments for index procedure accounted for the
largest share of total episode payment for PCI procedures ranging from 49.11% to 57.85%
across quartiles.
Payments for PCI episodes were higher for regions in the highest payment quartile
than those for the low-payment quartile across all payment components. In comparison to the
lowest payment quartile regions, the highest payment quartile regions had 31.41% higher
index procedure payments ($29,240 vs. $22,250), 26.17% higher professional payments
($6,875 vs. $5,449), 85.08% higher post-acute care payments ($16,195 vs. $8,750), 463.11%
higher readmission payments ($5,885 vs. $1,045), and 38.75% higher pharmacy payments
($1,340 vs. $966). Thus, payment difference between high- and low-payment regions for 90day PCI episode payments was greatest for readmission payments.
As for the drivers of these differences, index procedure 33.17% and post-acute care
35% contributed relatively similar proportions to the variation in total episode payment
between high-payment and low-payment regions. Readmission, professional services, postacute care, and pharmacy contributed 23%, 7%, and 2%, respectively to the variation in total
90-day episode payments between high- and low- payment region (see Table 26).
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Table 26: Payment Components and Variation of Average 90-Day Episode Payments for
CABG and PCI Procedures between High- and Low-Payment Regions.
Payment Component

Low Payment
Regions

High Payment
Regions

PCI (n=2691)
Index Procedure
22,250
Post-acute Care
8,750
Readmission
1,045
Professional Services
5,449
Pharmacy
966
Total Episode Payment
38,460
Note: Payments were estimated at regional level
*The absolute differences between high- and low-payment regions
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29,240
16,195
5,885
6,875
1,340
59,535

Difference*

6,990
7,444
4,840
1,426
374
21,075

% Variation

33%
35%
23%
7%
2%

DISCUSSION
With the CMS bundled payment models, including the 90-day clinical episodes of
care related to 32 conditions and procedures,[34, 69] private payers began to use such models to
drive improving patient outcomes and lowering healthcare costs.[42] The present study is one
of the few that has estimated 90-day episode payments for CABG surgery and PCI
procedures,[31, 51, 64] and it is the only one to be conducted for commercially insured patients
across Texas. In addition, commercial insurance payment data, rather than charge data, of a
representative commercially insured cohort was used in these analyses. Thus, it represents a
vital contribution to the literature, and its results are expected to provide strategies for private
payers as well as for healthcare providers that want to participate or implement bundled
payments.
As healthcare providers assume accountability for the quality and costs under bundled
payment programs, there are some implementation challenges from the provider’s
perspective as well as from the payer’s perspective. For example, there is a financial risk for
hospitals based on the 90-day period following an invasive procedure since a majority of that
period is for post-acute care. Therefore, a hospital, for example, that provides an index
procedure might bear a financial risk for the type of care provided after discharge, especially
if complications occur during the 90-day post-discharge period. Therefore, healthcare
providers from different disciplines and in multiple healthcare settings will need to
understand the financial risk areas around healthcare episodes to succeed under the episode
payment model. This risk-sharing could encourage better communication and enhance care
coordination among different healthcare settings responsible for the same episode of care. In
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response, healthcare providers will need to provide better care and improve patient outcomes,
which could be considered an advantage of the bundled payment model.
The episode payment model might create additional challenges. It might be difficult
to distribute payments among healthcare providers within the episode of care as these
payments usually belong to different providers in multiple healthcare settings. For episode
payments, one lump sum is reimbursed for all services related to the episode of care. Recent
efforts for bundled payments explain that such issues may be significant barriers for
implementing successful bundled payment.[44, 82] Nevertheless, some studies have found
significant payment reductions for other surgical procedures after implementing the bundled
payment model.[48, 49, 83]
Studies conducted on CABG and PCI episodes using Medicare data demonstrated
lower average payments of episodes than those episode payments from the present research
findings.[51, 55, 59, 61, 64] This variation was expected and supported in the literature,[66, 84] which
indicated that healthcare prices for commercially insured patients were substantially higher
than those for Medicare fee-for-service patients. To a certain degree, this variation has
occurred because Medicare pays healthcare providers based on a federally established
formula rather than on negotiated payment rates or on reported provider charges. Also,
Medicare uses DRGs as the basis for inpatient payments. The majority of commercial plans
do not follow the Medicare payment model of using DRGs for paying healthcare providers.
The logic in this present study of standardizing pricing is based on the Medicare regulatory
regime for paying providers. Another explanation for the results having higher mean episode
payments than those in previous studies could be related to the fact that all amounts of the
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present study were adjusted to 2018 U.S. dollars. Previous studies were conducted in earlier
study periods (see Table1) and economic factors, such as inflation, did not offset the change
in payments to 2018 U.S. dollars.
Furthermore, the literature suggested additional reasons for such differences in
payments between private and public payers.[85] First, the market power of healthcare
providers over private payers might be a reason for having higher payments than Medicare.
The market power of Medicare could have enabled it to enforce tighter limits on healthcare
providers’ payments. Another possible reason is the cost shift theory,[86] which implies that
public payers reimburse healthcare providers less than their costs, leading healthcare
providers to charge private payers well above costs to offset the losses from public payers.
Given the differences of the data sources and the study populations, the similarity of the
present study findings with those of previous studies suggested that wide variations existed in
episode payments for both CABG surgeries and PCI procedures.
When comparing commercial insurance payment amounts for CABG surgeries or PCI
procedures from the present study’s results with the charge amounts from the literature and
DSHS reports,[26, 52] a significant difference was observed. One study found the mean
hospital charge for PCI procedures was $88,350.[52] In 2016, the mean hospital charge for
PCI procedures in Texas was $126,823.[26] These charges were significantly higher than the
mean index PCI procedure (i.e., hospital) payment of $28,316 that was found in this current
study. In addition, there was a significant difference in amounts when comparing CABG
surgery charges with commercial insurance payments. The mean hospital charge for CABG
surgery in Texas was $234,560, which was substantially higher than the mean index CABG
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payment of $48,886.[26] Thus, it is vital to distinguish between the two terms, charges and
payments, when applying bundled payments.
Finally, the primary findings of this study regarding both 90-day CABG episodes and
90-day PCI episodes were established by aggregating episode payments and identifying
payment components. Applying this approach allowed looking beyond CABG surgery and
PCI procedure payments and gave us a comprehensive picture of post-discharge payments
for commercially insured patients in Texas.
Variation in Episode Payments
The first two findings of this study were related to comparative statistics, which were
performed to compare groups of episodes by patient characteristics. The results indicated
variabilities in episode payments by certain patient factors, including patient regions, type of
insurance, health plans, readmission stage, and comorbid conditions.
First, the results showed sufficient evidence that the 90-day CABG episode payment
for insured patients from at least one of the patient regions was different from the others. As
a result, the null hypothesis of Aim 1A was rejected. Second, the study confirmed the 90-day
PCI episode payment for commercially insured patients from at least one of the patient
regions was different from the other Texas regions. Thus, the null hypothesis of Aim 1B was
rejected.
Unpredictably, the study’s results demonstrated that males and females did not have
variability in the mean episode payments for either CABG surgeries or PCI procedures.
While the literature indicated that females were associated with higher payments, [51, 61, 87]
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there was also evidence in the literature that showed gender has no association with
payments.[76]
By comparing the findings of the present study using the proposed methodology to
measure costs (i.e., 90-day episode payment) with the findings of a previous study that used a
different method to measure costs (i.e., spending per member per year),[30] a consistency in
the conclusions was observed. In other words, there is evidence of the existence of regional
variations in healthcare costs across Texas. A previous report by the Institute of Medicine
(IOM) suggested that decreasing regional variations would result in a reduction of healthcare
expenditures.[88] William Edwards Deming, who is known as the father of quality
management, said, “If I had to reduce my message for management to just a few words, I’d
say it all had to do with reducing variation.”[89] By extension, efforts to reduce payment
variation for CABG surgeries and PCI procedures might yield significant savings as well as
improve efficiency.
Predictors of Episode Payments
Variation in CABG and PCI episode payments appeared to be influenced by multiple
patient factors, including patient region, age, certain comorbidities, readmissions, lengths of
stay, and insurance type (i.e., Medicare Advantage, commercial). The findings of the present
study were in an agreement with the findings of previous studies that showed patient factors
had an impact on CABG and PCI payments.[51, 52, 55, 59, 87] As the results demonstrated, based
on the existence of variability in CABG and PCI payments by patient regions, the performed
regression models have shown episode payments were lower for patients in the Austin region
than those for the patients in the Houston region. One explanation could be that Austin had a
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relatively lower readmission rate as compared to Houston or other Texas regions. Another
possible reason for the geographic variation in payments for CABG surgeries and PCI
procedures might be the regional differences in the supply of specialist physicians (e.g.,
number of cardiologists) and healthcare facilities (e.g., hospital beds), which may impact
demand. Furthermore, it was noticed that episode payments were lower for patients in the
Corpus Christi region than for patients in the Houston region.
However, age was surprisingly found to be negatively associated with episode
payments. Although age had a minimal overall association with payments in the present
study, this finding was contrary to expectations and findings from other studies. No evidence
in the literature was found suggesting that aging was negatively associated with episode
payment for CABG surgeries or PCI procedures. In fact, several previous studies revealed a
positive relationship between age and payments.[76, 87, 90] Another study showed that age had
a minimal overall association with cost.[61] One explanation could be that Medicare
Advantage patients, generally 65 years of age and older, had lower payments than
commercial patients of the study population. Another possible reason is that the results of the
present study could be attributed to myocardial infarction that was missed in younger patients
(when compared to older patients) due to a lower index of suspicion. Therefore, a delay
would have occurred in both the diagnosis and treatment of these patients. Such a delay could
have resulted in a more complicated course of the disease and may have prolonged the care
needed or health care utilizations in such patients, resulting in higher episode payments.
Previous studies also showed that healthcare spending for Medicare Advantage
patients was lower than those for commercially insured patients.[84, 91] The results of the
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present study agreed with the findings of these studies, which showed that payments for
Medicare Advantage patients were lower than those for commercially insured patients for
both CABG and PCI episodes. This could suggest that healthcare utilizations of Medicare
Advantage patients were lower than those of commercially insured patients. In other words,
it is possible that healthcare providers rendered a substantially lower volume of healthcare
services for Medicare Advantage insured patients than for commercially insured patients for
both CABG and PCI procedures. This could be because the health plan (i.e., PPO, POS)
might have had an impact on healthcare utilizations. This study found a strong collinearity
between the type of insurance product (i.e., commercial, Medicare Advantage) and the health
plan. It was more likely that a Medicare Advantage patient had a PPO health plan than a POS
plan. On the other hand, it was more likely that a commercial insurance patient had a POS
health plan than PPO health plan.
The results of the present study demonstrated that certain comorbid conditions were
associated with 90-day episode payments. These results were in line with the literature. The
regression model showed that CABG episode payments were 10% higher for patients with
peripheral vascular disease than for patients without this condition. However, the analysis
demonstrated that patients with a history of cerebrovascular disease were associated with
decreased 90-day CABG episode payments. No evidence in the literature was found
suggesting this finding. One possible explanation is that CAD and cerebrovascular have
similar pathophysiology. When patients with a history of cerebrovascular disease present
with chest pain, the index of suspicion for CAD is very high. Thus, they have a higher chance
of being diagnosed effectively and being treated earlier. For this reason, they would have a
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lower chance of complications, which would also result in reduced healthcare utilization and
payments. Furthermore, having high suspicion for CAD might lead to a more efficient
utilization (i.e., more appropriate, specific, and preventative healthcare) of the healthcare
services. A more efficient and effective healthcare delivery for these patients would
eventually result in lowering their overall payments as well.
For the PCI episode payments, the present study results showed that 90-day episode
payments for patients with renal disease were 18 % higher than those for patients without
renal disease. Additionally, the 90-day PCI episode payments for patients with diabetes with
chronic complications were 15% higher than those for patients without. Patients with
comorbidities that had a significant impact on costs could be considered under the highfinancial risk population when implementing bundled payments. Furthermore, strategies to
improve diabetes control and to pay additional attention to those with comorbid renal disease
conditions could effectively reduce 90-day PCI episode payments.
Moreover, the present study showed that length of stay and readmission were
significantly associated with higher payments for both CABG and PCI episodes. Being
readmitted is a predominant predictor of CABG and PCI episode payments. Episode
payments for readmitted CABG patients within a 30-day period, a 31-60-day period, and a
61-90-day period were higher than those for non-readmitted patients. Likewise, episode
payments for readmitted PCI patients within a 30-day period, a 31-60-day period, and a 6190-day period were higher than those for non-readmitted patients. By quantifying the costs of
readmission, this study highlighted the potential opportunities to provide more efficient care
and significantly improve the quality of care for CABG and PCI episodes across Texas
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regions. In fact, the CMS has focused on readmission as one of its main national healthcare
policies. For example, the Hospital Readmission Reduction Program, which is a Medicare
value-based purchasing program, supports the goal of linking payments to the quality of care
by seeking to penalize hospitals with high rates of readmissions for select conditions
Because readmission stage was the predominant predictor of CABG and PCI episode
payments, readmission rates across Texas were further analyzed. Among the regions, Austin
had the lowest readmission rate for CABG episodes, and Corpus Christi had the lowest
readmission rate for PCI episodes. The most common causes for 90-day readmissions for
both CABG surgeries and PCI procedures were identified by detecting the DRGs used for
readmissions. The most common DRG codes of readmissions for CABG episodes were 857,
603, 291, 293, and 863. Three of these DRG codes were related to postoperative infections
(i.e., 857, 603, 863), and two of these DRG codes were related to heart failure (i.e., 291,
293). These causes of readmissions were in line with the literature.[51] The present study also
showed a slightly higher readmission rate for CABG episode compared with another recent
study on 90-day CABG episode payment variation for TRICARE beneficiaries (14% vs.
13%).[31] Moreover, the most common DRG codes of readmissions for PCI episodes were
247, 287, 291, 246, and 236. The findings showed that the DRG code 247 was the most
common cause of readmission for PCI episodes, which was consistent with the literature.[64]
However, the present study showed a slightly lower readmission rate for PCI episodes
compared to another recent study on PCI episode payment variation (15.2% vs. 18.4%).[64]
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Drivers of Variation in Episode Payments
The third and fourth findings of this study demonstrated a considerable variation in
payments across Texas. There was a wide variation in average 90-day episode payments
across hospitals performing CABG surgery in Texas HRRs. The difference in average 90-day
payments at hospitals in the highest and lowest payment quartiles was $45,121, representing
73.9% higher payments at high-payment hospitals versus low-payment hospitals. Of the five
payment components, the index procedure was found to be the key driver of CABG episode
payment variation, contributing 48.6% of the total payment variation between high- and lowpayment hospitals. This finding was consistent with the reviewed studies that found the
primary driver of payment variation in CABG episode was related to index procedure.[31, 51,
55, 59]

The second key driver of payment variation was readmission, contributing 19.8% of the

total CABG episode payment variation between high- and low-payment hospitals. After this,
professional services and post-acute care contributed to the total payment variation by 17.2%
and 14.6%, respectively. The payment variation of professional services was driven in part
by surgery payments, followed by anesthesia, and E&M. As a result, this finding has fulfilled
Aim 2A of this research. Private payers and healthcare providers moving to the episode
payment model for CABG surgeries should consider modeling their sources of variation by
focusing on index hospitalizations.
The final finding of this study demonstrated a wide variation in average 90-day
episode payments across Texas hospitals performing PCI procedures. The difference in
average 90-day payments to hospitals in the highest and lowest payment quartiles was
$40,814, representing more than 100% higher payments at high-payment versus low99

payment hospitals. Of the five payment components, the index procedure was the key driver
of PCI episode payment variation, contributing 36.9% of the total payment variation between
high- and low-payment hospitals. Although the present study demonstrated that the primary
driver of the variation in PCI episode payments was related to the index procedure, the
component with the highest difference rate between high- and low-payment hospitals was
related to readmission (see Figure 10). This is in contrast to the study by Sukul et al. (2019)
(see Table 1), which examined the 90-day PCI episode payment and found that the
readmission payment was the primary driver of payment variation.[64] Finally, the present
study determined that the second key driver of payment variation was post-acute care,
contributing 35.8% of the total PCI episode payment variation between high and lowpayment hospitals. Post-acute care was driven in part by outpatient facility surgery as well as
by ancillary services (i.e., services and supplies, durable medical equipment, administered
drugs, and transportation services). With this final finding, this study has fulfilled Aim 2B of
this research. Private payers and healthcare providers moving to the episode payment model
for PCI procedures should understand the sources of payment variation by focusing on index
procedure, outpatient facility surgeries, and ancillary services.
Implications for Clinical Care, Quality Improvement, and Change in Practice
While CABG surgeries and PCI procedures were not in episode (bundled) payment
models for commercially insured patients, they may eventually become the first heart
procedure to be included. In 2018, the CMS included these procedures as new voluntary
episode payment models, which were qualified under the Medicare Quality Payment
Program.[34, 39, 69] This initiative by the CMS could incentivize healthcare providers entering
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episode payment models for CABG and PCI episodes. It could also motivate private payers
to adapt the episode payment method to align provider incentives toward improving
efficiency and healthcare quality. The findings of this research may contribute to the
literature by giving insight into the variation of both CABG and PCI episode payments across
commercially insured patient demographics and postoperative factors. Even though this
study did not determine how much savings could be achieved by implementing CABG and
PCI episode payments, it determined the type of services needed further investigation.
The 90-day episode payments for CABG surgeries and PCI procedures across Texas
appeared influenced by readmissions. A previous study showed a considerable proportion of
readmissions after PCI procedures could have been prevented.[92] Thus, this research also
highlighted opportunities for improvement and cost reductions. Because readmission is a
much more prominent factor in the 90-day episode payments, an excellent target for cost
reduction would to reduce readmissions. Strategies to contain the CABG and PCI episode
payments may need to differ depending on the main causes of readmission as well as on the
performance of hospitals with high readmission rates. For example, if linking payment to
healthcare performance within the episode of care helps reduce readmissions, which would
subsequently reduce payment, then this practice should be encouraged from a policy
perspective. Transferring some of the financial risk to healthcare providers might be helpful.
For example, holding healthcare providers finically accountable for high readmissions might
be more appropriate for reducing readmissions and, subsequently, episode payments.
Furthermore, healthcare policies, such as those that are relevant to improving the
transparency of healthcare performance and payment data available to patients, might help
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reduce payment variation. For example, when information about quality and payment,
including out-of-pocket expenses, are offered to patients, it could be used to incentivize
patients that need CABG or PCI procedures to request surgeries from high-quality healthcare
providers such as those hospitals with lower readmission rates. As a result, hospitals with
high readmissions could focus on improving their performance and reducing their
readmissions. Therefore, payments could be reduced.
Efforts to improve care for patients with certain comorbidities (e.g., renal disease,
diabetes with chronic complications, and peripheral vascular disease) would yield significant
savings. Insurers might stratify patients into categories based on their comorbid conditions
and severity of illness and then adjust episode payments based those that cost more. In
addition, clinical practice guidelines could be developed to manage certain comorbidities of
patients undergoing CABG surgeries or PCI procedures, such as conducting
multidisciplinary interactive sessions. The clinical care practices of 90-day episodes for
CABG surgeries and PCI procedures appeared to be lower in utilization in the Austin and
Corpus Christi regions than the other Texas regions. Their practices could be inspected and
shared with the healthcare settings in the Houston and in other high-cost regions in support of
an in-depth investigation and quality improvement.
Payment variations for CABG episodes and PCI episodes differ in terms of
contribution to 90-day payment variation between high- and low-cost hospitals. Across
Texas, high cost hospitals for CABG episodes were not necessarily high cost hospitals for
PCI episodes. Furthermore, high cost regions for CABG were not necessarily high cost
regions for PCI. These results suggested that policy makers should consider the
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characteristics of hospitals as well as regions when developing policies for healthcare
efficiency.
The present study’s findings also provided insight about the distribution of 90-day
episode payment across the five payment components for CABG surgeries and PCI
procedures. Index payments not only comprised the largest proportion of CABG and PCI
episode payments, but they also represented the key source of variations. The results of this
study demonstrated that index procedure payment was the primary driver of payment
variations. Thus, healthcare providers entering episode-based payment models for CABG and
PCI should consider the need to understand the key drivers of payment variation in CABG
and PCI episodes when developing initiatives to reduce related spending. Finally, this study
might contribute to defining the essential targets of payment reform and improving efficiency
in CABG and PCI episode.
Limitations
Although this study provided an understanding of costs for CABG surgeries and PCI
procedures for commercially insured patients in Texas, it was not without limitations. The
claims data were designed to justify payment, but they lacked the rich clinical details found
in patient medical charts. As a result, detailed clinical variables that could have affected
payments were not examined. This data, however, did include some valuable clinical
information (i.e., diagnosis and procedure codes) that was used to track comorbid conditions.
In addition, the present study also did not account for planned and unplanned readmissions.
This is similar to the limitations of another recent study in which bundled payment models
also did not exclude staged or planned PCIs from episodes of care.[64]
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Furthermore, the claims data used for this research did not allow for an examination
of the effectiveness of the two procedures (i.e., CABG and PCI) or for a clinical comparison
between them. They had limited clinical details and outcome measures. For this reason, no
inference could be made about to which extent undergoing CABG surgeries or PCI
procedures reflects high- or low-effectiveness. However, the aim of the present study was not
to determine the effectiveness of the two procedures (i.e., CABG and PCI). The two primary
aims of this research were to examine variation in CABG and PCI episode payments across
Texas and to examine the payment components that drive the variability.
Moreover, the datasets used for this study did not include information about the
deaths of patients. In response to this, episodes with fewer than two claims after the
discharge date were identified to ensure none of the study population died during index
hospitalization. There is, however, a possibility that some of the patients included in the
study died during the 90-day post-discharge.
Another limitation was that the claims data for this study did not include important
provider characteristics because of the payer-provider contractual agreements. For example,
the datasets did not include hospital zip codes, which could have affected the basis for
determining the exact geographic pattern of healthcare utilization. However, according to the
DAHC, most patients in the U.S. are generally admitted to hospitals close to where they
live.[29]
Finally, the study was limited to a particular group of privately insured patients in
Texas, which affects its generalizability to other populations outside of Texas. Despite these
limitations, patient demographics and operative predictors were considered while
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determining CABG and PCI episode payments and identifying the drivers of payment
variation across Texas. Thus, the claims data this study used were unique in that they
provided comprehensive payment information for a large and broadly representative
commercially insured population in Texas. As a result, this study might be generalizable to
other commercially insured populations in Texas.
CONCLUSIONS
This study simulated potential episode payments in patients who underwent CABG
surgeries and PCI procedures in Texas. It provided insight into CABG episode payment as
well as insight into the PCI episode payments across Texas. In addition, the present study
filled a knowledge gap by exploring the variation in CABG and PCI payments among
various factors of commercially insured patients in Texas. The findings indicated that both
CABG and PCI episode payments vary widely with the patients’ regions, ages, and
comorbidities. Payments also varied with other patient clinical factors, including length of
stay and readmission, as well as whether patients were using commercial insurance or
Medicare Advantage. Readmission was the most influential independent predictor of higher
payments for patients undergoing CABG surgeries and PCI procedures. These results have
contributed to a better understanding of the current variation of CABG and PCI payments
across Texas as well as to the present association of patient characteristics to total episode
payments. In other words, it was found that there were significant variations in episode
payments involved with patient characteristics.
This study reported that the variations in CABG and PCI episode payments between
low- and high-payment hospitals in Texas were mainly attributable to differences in index
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procedure payments. The findings of this study in the payment variation drivers may
contribute to an understanding of the current distribution of payments across both CABG and
PCI episodes. These drivers should be considered when developing initiatives to reduce
healthcare spending. They could also serve to inform policymakers, payers, and healthcare
providers about the implementation of bundled payment initiatives. The variation suggested
that within a bundled payment model, there may be considerable cost savings for the
healthcare system. These cost savings lie mainly within quality improvement programs to
ensure best practices and decrease readmissions.
This study could be replicated among other private payers in other states to allow for
conclusions that are more generalizable and robust. The findings of this study suggested the
need for in-depth research for hospital- and regional-level factors associated with 90-day
CABG and PCI episode payments. Further studies could provide valuable insights by
exploring the role of hospital and regional characteristics in predicting episode payments.
Finally, the findings of the present study might prove useful for a further understanding of
CABG and PCI episode payments in commercially insured patients in Texas, and they also
might encourage further studies to examine the comparative effectiveness of CABG surgeries
versus PCI procedures in this population.
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APPENDICES
Appendix A: Codes Used in the Data Extraction of the Study Population for CABG Episodes
Code Type
MS-DRG

HCPCS

Code
231
232
233
234
235
236
S2205

S2206

S2207

S2208

S2209

CPT

ICD 10

33510
33511
33512
33513
33514
33516
33517
33518
33519
33521
33522
33523
33533
33534
33535
33536
210093
210098
210099
211093
211098
211099
212093

Description
Coronary Bypass with PTCA with MCC
Coronary Bypass with PTCA without MCC
Coronary Bypass with Cardiac Cath with MCC
Coronary Bypass with Cardiac Cath without MCC
Coronary Bypass without Cardiac Cath with MCC
Coronary Bypass without Cardiac Cath without MCC
Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or
mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single
coronary arterial graft (S2205)
Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or
mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary
arterial grafts (S2206)
Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or
mini-sternotomy surgery, performed under direct vision; using venous graft only, single
coronary venous graft (S2207)
Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or
mini-sternotomy surgery, performed under direct vision; using single arterial and venous
graft(s), single venous graft (S2208)
Minimally invasive direct coronary artery bypass surgery involving mini- thoracotomy or
mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single
venous graft (S2209)
Under Venous Grafting Only for Coronary Artery Bypass
Coronary artery bypass, vein only
Coronary artery bypass, vein only
Venous Grafting Only for Coronary Artery Bypass.
Venous Grafting Only for Coronary Artery Bypass.
Venous Grafting Only for Coronary Artery Bypass
Combined Arterial-Venous Grafting for Coronary Bypass
Combined Arterial-Venous Grafting for Coronary Bypass
Combined Arterial-Venous Grafting for Coronary Bypass
Combined Arterial-Venous Grafting for Coronary Bypass
Combined Arterial-Venous Grafting for Coronary Bypass.
Combined Arterial-Venous Grafting for Coronary Bypass
Arterial Grafting for Coronary Artery Bypass.
Arterial Grafting for Coronary Artery Bypass
Arterial Grafting for Coronary Artery Bypass
Arterial Grafting for Coronary Artery Bypass.
Bypass Coronary Artery, One Site to Coronary Artery with
Bypass Coronary Artery, One Site to Right Internal Mammary
Bypass Coronary Artery, One Site to Left Internal Mammary
Bypass Coronary Artery, Two Sites to Coronary Artery with
Bypass Coronary Artery, Two Sites to Right Internal Mammary
Bypass Coronary Artery, Two Sites to Left Internal Mammary
Bypass Coronary Artery, Three Sites to Coronary Artery with
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212098
212099
213093
213098
213099
021009C
021009F
021009W
02100A3
02100A8
02100A9
02100AC
02100AF
02100AW
02100J3
02100J8
02100J9
02100JC
02100JF
02100JW
02100K3
02100K8
02100K9
02100KC
02100KF
02100KW
02100Z3
02100Z8
02100Z9
02100ZC
02100ZF
021109C
021109F
021109W
02110A3
02110A8
02110A9
02110AC
02110AF
02110AW
02110J3
02110J8
02110J9
02110JC
02110JF

Bypass Coronary Artery, Three Sites to Right Internal Mammary
Bypass Coronary Artery, Three Sites to Left Internal Mammary
Bypass Coronary Artery, Four or More Sites to Coronary Artery
Bypass Coronary Artery, Four or More Sites to Right Internal Mammary with Autologous
Venous Tissue, Open Approach
Bypass Coronary Artery, Four or More Sites to Left Internal Mammary with Autologous
Venous Tissue, Open Approach
Bypass Coronary Artery, One Site to Thoracic Artery with
Bypass Coronary Artery, One Site to Abdominal Artery with
Bypass Coronary Artery, One Site to Aorta with Autologous
Bypass Coronary Artery, One Site to Coronary Artery with
Bypass Coronary Artery, One Site to Right Internal Mammary
Bypass Coronary Artery, One Site to Left Internal Mammary
Bypass Coronary Artery, One Site to Thoracic Artery with
Bypass Coronary Artery, One Site to Abdominal Artery with
Bypass Coronary Artery, One Site to Aorta with Autologous
Bypass Coronary Artery, One Site to Coronary Artery with
Bypass Coronary Artery, One Site to Right Internal Mammary
Bypass Coronary Artery, One Site to Left Internal Mammary with
Bypass Coronary Artery, One Site to Thoracic Artery with
Bypass Coronary Artery, One Site to Abdominal Artery with
Bypass Coronary Artery, One Site to Aorta with Synthetic
Bypass Coronary Artery, One Site to Coronary Artery with
Bypass Coronary Artery, One Site to Right Internal Mammary
Bypass Coronary Artery, One Site to Left Internal Mammary
Bypass Coronary Artery, One Site to Thoracic Artery with
Bypass Coronary Artery, One Site to Abdominal Artery with
Bypass Coronary Artery, One Site to Aorta with Nonautologous
Bypass Coronary Artery, One Site to Coronary Artery, Open
Bypass Coronary Artery, One Site to Right Internal Mammary,
Bypass Coronary Artery, One Site to Left Internal Mammary,
Bypass Coronary Artery, One Site to Thoracic Artery, Open
Bypass Coronary Artery, One Site to Abdominal Artery, Open
Bypass Coronary Artery, Two Sites to Thoracic Artery with
Bypass Coronary Artery, Two Sites to Abdominal Artery with
Bypass Coronary Artery, Two Sites to Aorta with Autologous
Bypass Coronary Artery, Two Sites to Coronary Artery with
Bypass Coronary Artery, Two Sites to Right Internal Mammary
Bypass Coronary Artery, Two Sites to Left Internal Mammary
Bypass Coronary Artery, Two Sites to Thoracic Artery with
Bypass Coronary Artery, Two Sites to Abdominal Artery with
Bypass Coronary Artery, Two Sites to Aorta with Autologous
Bypass Coronary Artery, Two Sites to Coronary Artery with
Bypass Coronary Artery, Two Sites to Right Internal Mammary
Bypass Coronary Artery, Two Sites to Left Internal Mammary
Bypass Coronary Artery, Two Sites to Thoracic Artery with
Bypass Coronary Artery, Two Sites to Abdominal Artery with
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02110JW
02110K3
02110K8
02110K9
02110KC
02110KF
02110KW
02110Z3
02110Z8
02110Z9
02110ZC
02110ZF
021209C
021209F
021209W
02120A3
02120A8
02120A9
02120AC
02120AF
02120AW
02120J3
02120J8
02120J9
02120JC
02120JF
02120JW
02120K3
02120K8
02120K9
02120KC
02120KF
02120KW
02120Z3
02120Z8
02120Z9
02120ZC
02120ZF
021309C
021309F
021309W
02130A3
02130A8
02130A9
02130AC

Bypass Coronary Artery, Two Sites to Aorta with Synthetic
Bypass Coronary Artery, Two Sites to Coronary Artery with
Bypass Coronary Artery, Two Sites to Right Internal Mammary
Bypass Coronary Artery, Two Sites to Left Internal Mammary
Bypass Coronary Artery, Two Sites to Thoracic Artery with
Bypass Coronary Artery, Two Sites to Abdominal Artery with
Bypass Coronary Artery, Two Sites to Aorta with
Bypass Coronary Artery, Two Sites to Coronary Artery, Open
Bypass Coronary Artery, Two Sites to Right Internal Mammary,
Bypass Coronary Artery, Two Sites to Left Internal Mammary,
Bypass Coronary Artery, Two Sites to Thoracic Artery, Open
Bypass Coronary Artery, Two Sites to Abdominal Artery, Open
Bypass Coronary Artery, Three Sites to Thoracic Artery with
Bypass Coronary Artery, Three Sites to Abdominal Artery with
Bypass Coronary Artery, Three Sites to Aorta with Autologous
Bypass Coronary Artery, Three Sites to Coronary Artery with
Bypass Coronary Artery, Three Sites to Right Internal Mammary
Bypass Coronary Artery, Three Sites to Left Internal Mammary
Bypass Coronary Artery, Three Sites to Thoracic Artery with
Bypass Coronary Artery, Three Sites to Abdominal Artery with
Bypass Coronary Artery, Three Sites to Aorta with Autologous
Bypass Coronary Artery, Three Sites to Coronary Artery with
Bypass Coronary Artery, Three Sites to Right Internal Mammary
Bypass Coronary Artery, Three Sites to Left Internal Mammary
Bypass Coronary Artery, Three Sites to Thoracic Artery with
Bypass Coronary Artery, Three Sites to Abdominal Artery with
Bypass Coronary Artery, Three Sites to Aorta with Synthetic
Bypass Coronary Artery, Three Sites to Coronary Artery with
Bypass Coronary Artery, Three Sites to Right Internal Mammary
Bypass Coronary Artery, Three Sites to Left Internal Mammary
Bypass Coronary Artery, Three Sites to Thoracic Artery with
Bypass Coronary Artery, Three Sites to Abdominal Artery with
Bypass Coronary Artery, Three Sites to Aorta with
Bypass Coronary Artery, Three Sites to Coronary Artery, Open
Bypass Coronary Artery, Three Sites to Right Internal Mammary,
Bypass Coronary Artery, Three Sites to Left Internal Mammary,
Bypass Coronary Artery, Three Sites to Thoracic Artery, Open
Bypass Coronary Artery, Three Sites to Abdominal Artery, Open
Bypass Coronary Artery, Four or More Sites to Thoracic Artery
Bypass Coronary Artery, Four or More Sites to Abdominal Artery with Autologous Venous
Tissue, Open Approach
Bypass Coronary Artery, Four or More Sites to Aorta with
Bypass Coronary Artery, Four or More Sites to Coronary Artery
Bypass Coronary Artery, Four or More Sites to Right Internal Mammary with Autologous
Arterial Tissue, Open Approach
Bypass Coronary Artery, Four or More Sites to Left Internal Mammary with Autologous
Arterial Tissue, Open Approach
Bypass Coronary Artery, Four or More Sites to Thoracic Artery
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02130AF
02130AW
02130J3
02130J8
02130J9
02130JC
02130JF
02130JW
02130K3
02130K8
02130K9
02130KC
02130KF

ICD-9

02130KW
02130Z3
02130Z8
02130Z9
02130ZC
02130ZF
36.1
36.11
36.12
36.13
36.14
36.15
36.16
36.17
36.19
36.2

Bypass Coronary Artery, Four or More Sites to Abdominal Artery with Autologous Arterial
Tissue, Open Approach
Bypass Coronary Artery, Four or More Sites to Aorta with Autologous Arterial Tissue, Open
Approach
Bypass Coronary Artery, Four or More Sites to Coronary Artery
Bypass Coronary Artery, Four or More Sites to Right Internal
Bypass Coronary Artery, Four or More Sites to Left Internal
Bypass Coronary Artery, Four or More Sites to Thoracic Artery
Bypass Coronary Artery, Four or More Sites to Abdominal Artery
Bypass Coronary Artery, Four or More Sites to Aorta with
Bypass Coronary Artery, Four or More Sites to Coronary Artery
Bypass Coronary Artery, Four or More Sites to Right Internal Mammary with Nonautologous
Tissue Substitute, Open Approach
Bypass Coronary Artery, Four or More Sites to Left Internal Mammary with Nonautologous
Tissue Substitute, Open Approach
Bypass Coronary Artery, Four or More Sites to Thoracic Artery
Bypass Coronary Artery, Four or More Sites to Abdominal Artery with Nonautologous
Tissue Substitute, Open Approach
Bypass Coronary Artery, Four or More Sites to Aorta with
Bypass Coronary Artery, Four or More Sites to Coronary Artery,
Bypass Coronary Artery, Four or More Sites to Right Internal
Bypass Coronary Artery, Four or More Sites to Left Internal
Bypass Coronary Artery, Four or More Sites to Thoracic Artery,
Bypass Coronary Artery, Four or More Sites to Abdominal
Aortocoronary bypass NOS
Aortocor bypas-1 cor art
Aortocor bypas-2 cor art
Aortocor bypas-3 cor art
Aortcor bypas-4+ cor art
1 int mam-cor art bypass
2 int mam-cor art bypass
Abd-coron artery bypass
Hrt revas byps anas NEC
Arterial implant revasc

Note: CPT-4, Current Procedural Terminology 4; ICD-10-CM, International Classification of Diseases, 10th Revision;
ICD-9, International Classification of Diseases, 9th Revision; MS-DRG, Medicare Severity Diagnosis Related Groups;
HCPCS, Healthcare Common Procedure Coding System
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Appendix B: Codes Used in the Data Extraction of the Study Population for PCI Episodes
Code
System
MS-DRG

Code
246
247
248
249
250
251

HCPCS

273
274
92920
C9600

C9604

92937

92924
92928

Percutaneous Cardiovascular Procedures with Drug-Eluting Stent with MCC
or 4+ Arteries or Stents
Percutaneous Cardiovascular Procedures with Drug-Eluting Stent without
MCC
Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent with
MCC or 4+ Arteries or Stents
Percutaneous Cardiovascular Procedures with Non-Drug-Eluting Stent
without MCC
Percutaneous Cardiovascular Procedures without Coronary Artery Stent with
MCC
Percutaneous Cardiovascular Procedures without Coronary Artery Stent
without MCC
Percutaneous Intracardiac Procedures with MCC
Percutaneous Intracardiac Procedures without MCC
Percutaneous transluminal coronary angioplasty; single major coronary
artery or branch
Percutaneous transcatheter placement of drug eluting intracoronary stent(s),
with coronary angioplasty when performed; single major coronary artery or
branch
Percutaneous transluminal revascularization of or through coronary artery
bypass graft (internal mammary, free arterial, venous), any combination of
drug
Percutaneous transluminal revascularization of or through coronary artery
bypass graft (internal mammary, free arterial, venous), any combination of
intracoronary stent, atherectomy and angioplasty, including distal protection
when performed; single vessel
Percutaneous transluminal coronary atherectomy, with coronary angioplasty
when performed; single major coronary artery or branch

92941

Percutaneous transcatheter placement of intracoronary stent(s), with
coronary angioplasty when performed; single major coronary artery or
branch
Percutaneous transluminal revascularization of chronic total occlusion,
coronary artery, coronary artery branch, or coronary artery bypass graft, any
combination of intracoronary stent, atherectomy and angioplasty; single
vessel
Percutaneous transluminal revascularization of acute total/subtotal occlusion
during acute myocardial infarction, coronary artery or coronary artery bypass
graft, any combination of drug
Percutaneous transluminal coronary atherectomy, with intracoronary stent,
with coronary angioplasty when performed; single major coronary artery or
branch
Percutaneous transluminal revascularization of chronic total occlusion,
coronary artery, coronary artery branch, or coronary artery bypass graft, any
combination of drug
Percutaneous transluminal coronary atherectomy, with drug eluting
intracoronary stent, with coronary angioplasty when performed; single major
coronary artery or branch
Coronary Therapeutic Services and Procedures

92943

Coronary Therapeutic Services and Procedures

92980

Coronary Therapeutic Services and Procedures

92943

C9606

92933

C9607

C9602

CPT

Description
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ICD-10

92982

Coronary Therapeutic Services and Procedures

92995

Coronary Therapeutic Services and Procedures

270346

Dilation of Coronary Artery, One Site, Bifurcation, with Drug‐

270446

Dilation of Coronary Artery, One Site, Bifurcation, with Drug‐ eluting
Intraluminal Device, Percutaneous Endoscopic Approach

271346

Dilation of Coronary Artery, Two Sites, Bifurcation, with Drug‐

271446

Dilation of Coronary Artery, Two Sites, Bifurcation, with Drug‐ eluting
Intraluminal Device, Percutaneous Endoscopic Approach

272346

Dilation of Coronary Artery, Three Sites, Bifurcation, with Drug‐

272446

Dilation of Coronary Artery, Three Sites, Bifurcation, with Drug‐ eluting
Intraluminal Device, Percutaneous Endoscopic Approach

273346

Dilation of Coronary Artery, Four or More Sites, Bifurcation, with Drug‐
eluting Intraluminal Device, Percutaneous Approach

273446

Dilation of Coronary Artery, Four or More Sites, Bifurcation, with Drug‐
eluting Intraluminal Device, Percutaneous Endoscopic Approach

027034Z

Dilation of Coronary Artery, One Site with Drug‐eluting

02703D6

Dilation of Coronary Artery, One Site, Bifurcation, with

02703DZ

Dilation of Coronary Artery, One Site with Intraluminal Device,

02703T6

Dilation of Coronary Artery, One Site, Bifurcation, with

02703TZ

Dilation of Coronary Artery, One Site with Radioactive

02703Z6

Dilation of Coronary Artery, One Site, Bifurcation, Percutaneous

02703ZZ

Dilation of Coronary Artery, One Site, Percutaneous Approach

027044Z

Dilation of Coronary Artery, One Site with Drug‐eluting

02704D6

Dilation of Coronary Artery, One Site, Bifurcation, with

02704DZ

Dilation of Coronary Artery, One Site with Intraluminal Device,

02704T6

Dilation of Coronary Artery, One Site, Bifurcation, with Radioactive
Intraluminal Device, Percutaneous Endoscopic Approach

02704TZ

Dilation of Coronary Artery, One Site with Radioactive

02704Z6

Dilation of Coronary Artery, One Site, Bifurcation, Percutaneous

02704ZZ

Dilation of Coronary Artery, One Site, Percutaneous Endoscopic

027134Z

Dilation of Coronary Artery, Two Sites with Drug‐eluting

02713D6

Dilation of Coronary Artery, Two Sites, Bifurcation, with

02713DZ

Dilation of Coronary Artery, Two Sites with Intraluminal Device,

02713T6

Dilation of Coronary Artery, Two Sites, Bifurcation, with

02713TZ

Dilation of Coronary Artery, Two Sites with Radioactive

02713Z6

Dilation of Coronary Artery, Two Sites, Bifurcation,

02713ZZ

Dilation of Coronary Artery, Two Sites, Percutaneous Approach

027144Z

Dilation of Coronary Artery, Two Sites with Drug‐eluting

02714D6

Dilation of Coronary Artery, Two Sites, Bifurcation, with

02714DZ

Dilation of Coronary Artery, Two Sites with Intraluminal Device,
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02714T6

Dilation of Coronary Artery, Two Sites, Bifurcation, with Radioactive
Intraluminal Device, Percutaneous Endoscopic Approach

02714TZ

Dilation of Coronary Artery, Two Sites with Radioactive

02714Z6

Dilation of Coronary Artery, Two Sites, Bifurcation,

02714ZZ

Dilation of Coronary Artery, Two Sites, Percutaneous

027234Z

Dilation of Coronary Artery, Three Sites with Drug‐eluting

02723D6

Dilation of Coronary Artery, Three Sites, Bifurcation, with

02723DZ

Dilation of Coronary Artery, Three Sites with Intraluminal

02723T6

Dilation of Coronary Artery, Three Sites, Bifurcation, with

02723TZ

Dilation of Coronary Artery, Three Sites with Radioactive

02723Z6

Dilation of Coronary Artery, Three Sites, Bifurcation,

02723ZZ

Dilation of Coronary Artery, Three Sites, Percutaneous

027244Z

Dilation of Coronary Artery, Three Sites with Drug‐eluting

02724D6

Dilation of Coronary Artery, Three Sites, Bifurcation, with

02724DZ

Dilation of Coronary Artery, Three Sites with Intraluminal

02724T6

Dilation of Coronary Artery, Three Sites, Bifurcation, with Radioactive
Intraluminal Device, Percutaneous Endoscopic Approach

02724TZ

Dilation of Coronary Artery, Three Sites with Radioactive Intraluminal
Device, Percutaneous Endoscopic Approach

02724Z6

Dilation of Coronary Artery, Three Sites, Bifurcation,

02724ZZ

Dilation of Coronary Artery, Three Sites, Percutaneous

027334Z

Dilation of Coronary Artery, Four or More Sites with Drug‐

02733D6

Dilation of Coronary Artery, Four or More Sites, Bifurcation,

02733DZ

Dilation of Coronary Artery, Four or More Sites with

02733T6

Dilation of Coronary Artery, Four or More Sites, Bifurcation, with
Radioactive Intraluminal Device, Percutaneous Approach

02733TZ

Dilation of Coronary Artery, Four or More Sites with Radioactive

02733Z6

Dilation of Coronary Artery, Four or More Sites, Bifurcation,

02733ZZ

Dilation of Coronary Artery, Four or More Sites, Percutaneous

027344Z

Dilation of Coronary Artery, Four or More Sites with Drug‐ eluting
Intraluminal Device, Percutaneous Endoscopic Approach

02734D6

Dilation of Coronary Artery, Four or More Sites, Bifurcation, with
Intraluminal Device, Percutaneous Endoscopic Approach

02734DZ

Dilation of Coronary Artery, Four or More Sites with

02734T6

Dilation of Coronary Artery, Four or More Sites, Bifurcation, with
Radioactive Intraluminal Device, Percutaneous Endoscopic Approach

02734TZ

Dilation of Coronary Artery, Four or More Sites with Radioactive
Intraluminal Device, Percutaneous Endoscopic Approach

02734Z6

Dilation of Coronary Artery, Four or More Sites, Bifurcation,

02734ZZ

Dilation of Coronary Artery, Four or More Sites, Percutaneous
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ICD-9

0.66

PTCA

36.06

Ins nondrug elut cor st

36.07

Ins drug‐elut coronry st

Note: CPT 4, Current Procedural Terminology 4; ICD-10-CM, International Classification of
Diseases, 10th Revision; ICD-9, International Classification of Diseases, 9th Revision; MS-DRG,
Medicare Severity Diagnosis Related Groups; HCPCS, Healthcare Common Procedure Coding System
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Appendix C: Codes to Identify the Presence of Each Condition in the Adapted Charlson
Comorbidity Index
Score
Weights*
1

Description

Code (ICD-9-CM)

ICD-10

Myocardial infarction

410.X, 412.X

I21.X, I22.X, I25.2

1

Congestive heart failure

I09.9, I11.0, I13.0, I13.2,
I25.5, I42.0, I42.5-I42.9,
I43.X, I50.X, P29.0

1

Peripheral vascular disease

398.91, 402.01, 402.11, 402.91,
404.01, 404.03, 404.11, 404.13,
404.91, 404.93, 425.4-425.9,
428.X
093.0, 437.3, 440.X, 441.X,
443.1-443.9, 447.1, 557.1, 557.9,
V43.4

1

Cerebrovascular disease

362.34, 430.X-438.X

2

Dementia

290.X, 294.1, 331.2

1

Chronic pulmonary disease

416.8, 416.9, 490.X-505.X,
506.4, 508.1, 508.8

1

Rheumatologic disease

446.5, 710.0-710.4, 714.0-714.2,
714.8, 725.X

1

Peptic ulcer disease

531.X-534.X

1*

Mild liver disease

1**

Diabetes without chronic
complications

070.22, 070.23, 070.32, 070.33,
070.44, 070.54, 070.6, 070.9,
570.X, 571.X, 573.3, 573.4,
573.8, 573.9, V42.7
250.0-250.3, 250.8, 250.9

2

Diabetes with chronic
complications

250.4-250.7

1

Hemiplegia or paraplegia

334.1, 342.X, 343.X, 344.0344.6, 344.9

2

Renal disease

2

Any malignancy, including
lymphoma and leukemia, except
malignant neoplasm of skin

403.01, 403.11, 403.91, 404.02,
404.03, 404.12, 404.13, 404.92,
404.93, 582.X, 583.0-583.7,
585.X, 586.X, 588.0, V42.0,
V45.1, V56.X
140.X-172.X, 174.X-195.8,
200.X-208.X, 238.6
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I70.X, I71.X, I73.1, I73.8,
I73.9, I77.1, I79.0, I79.2,
K55.1, K55.8, K55.9, Z95.8,
Z95.9
G45.X, G46.X, H34.0, I60.XI69.X
F00.X-F03.X, F05.1, G30.X,
G31.1
I27.8, I27.9, J40.X-J47.X,
J60.X-J67.X, J68.4, J70.1,
J70.3
M05.X, M06.X, M31.5,
M32.X-M34.X, M35.1,
M35.3, M36.0
K25.X-K28.X
B18.X, K70.0-K70.3, K70.9,
K71.3-K71.5, K71.7, K73.X,
K74.X, K76.0, K76.2-K76.4,
K76.8, K76.9, Z94.4
E10.0, E10.L, E10.6, E10.8,
E10.9, E11.0, E11.1, E11.6,
E11.8, E11.9, E12.0, E12.1,
E12.6, E12.8, E12.9, E13.0,
E13.1, E13.6, E13.8, E13.9,
E14.0, E14.1, E14.6, E14.8,
E14.9
E10.2-E10.5, E10.7, E11.2E11.5, E11.7, E12.2-E12.5,
E12.7, E13.2-E13.5, E13.7,
E14.2-E14.5, E14.7
G04.1, G11.4, G80.1, G80.2,
G81.X, G82.X, G83.0-G83.4,
G83.9
I12.0, I13.1, N03.2-N03.7,
N05.2-N05.7, N18.X, N19.X,
N25.0, Z49.0-Z49.2, Z94.0,
Z99.2
C00.X-C26.X, C30.X-C34.X,
C37.X-C41.X, C43.X, C45.XC58.X, C60.X-C76.X, C81.XC85.X, C88.X, C90.X-C97.X

3

Moderate or severe liver disease

456.0-456.2, 572.2-572.8

6

Metastatic solid tumor

196.X-199.X

I85.0, I85.9, I86.4, I98.2,
K70.4, K71.1, K72.1, K72.9,
K76.5, K76.6, K76.7
C77.X-C80.X

6

AIDS/HIV

042.X-044.X

B20.X-B22.X, B24.X

Note: Adapted from the data dictionary of Optum claims data.[72, 74, 75]
* If a patient found to have diabetes with chronic complication, the weight of diabetes without chronic complication was
changed to 0
** If a patient found to have moderate or severe liver disease, the weight of mild liver disease was changed 0
(i.e., the minimum possible CCI score was 0 while the maximum possible CCI score was 31)
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Appendix D: Personal Consumption Expenditures: Health (Chain-type price index)

Index Value
$101.00

$100
$100.00
$99.00

$98.20

$98.00
$96.70

$97.00
$96.00

$95.60
$95.10

$95.00
$94.00
$93.00
$92.00
Index Value

2014

2015

2016

2017

2018

$95.10

$95.60

$96.70

$98.20

$100

Note: Unit index 2018 = $100; Adapted from “U.S. Bureau of Economic Analysis” [70]
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Appendix E: Variable Descriptions of the Extracted Claims Data
VARIABLE

DESCRIPTION

TYPE

PATID

An encrypted, system-generated number that identifies an individual across multiple
groups/policies. This identifier is not derived from information about the individual and is
compliant with HIPAA §164.514c.

Num

BUS

Identifies the type of business the product is intended to service.

Char

ELIGEFF

The date this member coverage row of information is effective.

Num

ELIGEND

The date this member coverage row of information ended (or will end).

Num

GDR_CD

A code identifying the sex of the member M=male, F=female, U=unknown

Char

PRODUCT

The code commonly used by the health care industry to identify the product.

Char

YRDOB

The member's year of birth, capped at 90 years.

Num

ZIPCODE_5

Collapsed 5-digit postal zip code developed from statistical analysis of US Census data. 5digit zip codes are either presented alone, collapsed into other 5-digit zip codes, or not
reported depending on the statistical analysis results.

Char

CLMID

Encrypted Claim ID. A provider can bill multiple revenue codes for services rendered on
one claim. Each revenue code will generate a claim line. Providers typically submit
separate claim for each visit they have with a patient.

Char

CLMSEQ

Number assigned in the source system to the service within the claim. This field is used to
distinguish between the detail records for a claim. Use with CLMID

Char

DRG

The Diagnosis Related Group (DRG) Code assigned by the source system. A DRG
classifies patients by diagnostic or surgical procedure into major diagnostic categories for
the purpose of determining payment of hospitalization charges. Effective 10/1/2007, the
Centers for Medicare and Medicaid Services (CMS) introduced the MS-DRG code set and
retired the CMS-DRG set. The new code set refined the DRGs based on the presence of
complications or co-morbidities. One effect of this change is that the MS-DRG descriptions
are completely different from previous descriptions. The DRG code table contains
historical CMS-DRGs as well as MS-DRG codes.

Char

FST_DT

The beginning date for the service, event, or confinement being billed by the provider.

Num

ICD_FLAG

ICD Version Code will distinguish between ICD-9 and ICD-10 codes.

Char

LST_DT

The service date for the service, event, or confinement being billed by the provider

Num

PROV

A unique system-generated number that identified the provider. It is possible for a provider
to have multiple IDs or an ID to point to multiple physicians, particularly in the case of
group practice.

Num

STD_COST

An estimate of the allowed amount for the facility charges related to the confinement.
Associated surgeon's fees are likely to be found in the medical table.

Num

TOS_CD

Type of Service Code

Char

PROC

Claim Level 1 ICD-X procedure code off of the header portion of the claim

Char

PROC1

First ICD-X Proc Code

Char

PROC2

Second ICD-X Proc Code

Char

PROC3

Third ICD-X Proc Code

Char

PROC4

Fourth ICD-X Proc Code

Char

PROC5

Fifth ICD-X Proc Code

Char
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LOS

Length of Stay from start of first confinement record to end of last confinement record

Num

DIAG1

First ICD-X Diagnosis

Char

DIAG2

Second ICD-X Diagnosis

Char

DIAG3

Third ICD-X Diagnosis

Char

DIAG4

Fourth ICD-X Diagnosis

Char

DIAG5

Fifth ICD-X Diagnosis

Char

DISCH_DATE

Discharge Date of Confinement (YYYYMMDD)

Num

CONF_ID

Confinement Identifier. Used to identify claims records associated with an inpatient
hospitalization. This data element is encrypted.

Char

ADMIT_DATE

Admission Date of Confinement (YYYYMMDD)

Num

DIAG_DESC

Describes the International Classification of Disease, 10th/9th Revision, Clinical
Modification (ICD-9-CM/ICD-10-CM) code. ICD-9-CM/ICD-10-CM is designed for the
classification of morbidity and mortality information for statistical purposes and for the
indexing of hospital records by disease and operations, for data storage retrieval. ICD-9CM/ICD-10-CM is an accepted national standard for coding diagnostic and disease
information.
Describes a specific procedure performed or service provided. A procedure code can be an
ICD10/ICD9, CPT©, or HCPCS Level II code.

Char

PROC_DESC

Note: adapted from the data dictionary of Optum claims data
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Char

Appendix F: Acute Myocardial Infarction Codes
Code Type

Number

Description

ICD-9

41000

Acute Myocardial Infarction of Anterolateral Wall Episode of Care Unspecified

ICD-9

41001

Acute Myocardial Infarction of Anterolateral Wall Initial Episode of Care

ICD-9

41010

Acute Myocardial Infarction of Other Anterior Wall Episode of Care Unspecified

ICD-9

41011

Acute myocardial infarction of other anterior wall, initial episode of care

ICD-9

41020

Acute Myocardial Infarction of Inferolateral Wall Episode of Care Unspecified

ICD-9

41021

Acute myocardial infarction of inferolateral wall, initial episode of care

ICD-9

41030

Acute Myocardial Infarction of Inferoposterior Wall Episode of Care Unspecified

ICD-9

41031

Acute myocardial infarction of inferoposterior wall, initial episode of care

ICD-9

41040

Acute Myocardial Infarction of Other Inferior Wall Episode of Care Unspecified

ICD-9

41041

Acute myocardial infarction of other inferior wall, initial episode of care

ICD-9

41050

Acute Myocardial Infarction of Other Lateral Wall Episode of Care Unspecified

ICD-9

41051

Acute myocardial infarction of other lateral wall, initial episode of care

ICD-9

41060

True Posterior Wall Infarction Episode of Care Unspecified

ICD-9

41061

True posterior wall infarction, initial episode of care

ICD-9

41070

Subendocardial Infarction Episode of Care Unspecified

ICD-9

41071

Subendocardial infarction, initial episode of care

ICD-9

41080

Acute Myocardial Infarction of Other Specified Sites Episode of Care Unspecified

ICD-9

41081

Acute myocardial infarction of other specified sites, initial episode of care

ICD-9

41090

Acute Myocardial Infarction of Unspecified Site Episode of Care Unspecified

ICD-9

41091

Acute myocardial infarction of unspecified site, initial episode of care

ICD-10

I2101

ST Elevation (STEMI) Myocardial Infarction Involving Left Main Coronary Artery

ICD-10

I2102

ST Elevation (STEMI) Myocardial Infarction Involving Left Anterior Descending Coronary Artery

ICD-10

I2109

ST Elevation (STEMI) Myocardial Infarction Involving Other Coronary Artery of Anterior Wall

ICD-10

I2111

ST Elevation (STEMI) Myocardial Infarction Involving Right Coronary Artery

ICD-10

I2119

ST Elevation (STEMI) Myocardial Infarction Involving Other Coronary Artery of Inferior Wall

ICD-10

I2121

ST Elevation (STEMI) Myocardial Infarction Involving Left Circumflex Coronary Artery

ICD-10

I2129

ST Elevation (STEMI) Myocardial Infarction Involving Other Sites

ICD-10

I213

ST Elevation (STEMI) Myocardial Infarction of Unspecified Site

ICD-10

I214

Non-ST Elevation (NSTEMI) Myocardial Infarction

ICD-10

I220

Subsequent ST Elevation (STEMI) Myocardial Infarction of Anterior Wall

ICD-10

I221

Subsequent ST Elevation (STEMI) Myocardial Infarction of Inferior Wall

ICD-10

I222

Subsequent Non-ST Elevation (NSTEMI) Myocardial Infarction

ICD-10

I228

Subsequent ST Elevation (STEMI) Myocardial Infarction of Other Sites

ICD-10

I229

Subsequent ST Elevation (STEMI) Myocardial Infarction of Unspecified Site

Note: Reprinted from “Drivers of Variation in 90-Day Episode Payments After Percutaneous Coronary Intervention”[64], by
Sukul, D., 2019, Circulation. Cardiovascular Interventions, 12(1), e006928.
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